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ABSTRACT
Pharmaceuticals are • fwldamental componcz:llofbcalth care deli \'ay in toda y's
soaet}'. Yet the neces.sity and appropriateness oftbeirpRSCription is 50mCtimcs
questio nable. We performed two pilot studies to dclcnnine the feutbility of: (I )
collecti ng pa tien t speci fic data from physicians. (2) applying clinical practice guidelines
10 fami ly physicians' thcnpeutic decisiofts and (3 ) using . trained resc:an:h team versus
an expert pand comeasure the appropr1atenessofthcse deci siON . These studies Ca)
exami ned th e uti lization of drugs for upper psIl'Ointestinal (01) disorders MId(b)
antimicro bial agents. In both studies two panels assessed the physicians ' diagnostic and
treatment deci sions. To assess appropriumess of these decisions an expert panel used
implicit cl in ical judgement and• research team app lied explicit criterion-based
guidelines . Com pari sons a f the deci sions made by these two panels determined that it is
feasibl e for a research team to app ly guiddincs to pabcm specific data and make
decisions reg ard ing the optimal treatment regime for-patients examined.
The first stud y examined the use o f drugs effectiv e in the tratmenI o f upper G I
disorders as prescribed by six fam ily physicians . The treatment dec::istom madeby the
physicians and subsequently j ud ged by two panels showed that the panel s Jlgrecd 9S~. o f
the time on the optimality a f me physicians ' decisions. From the hlgh levd of agreement
we conclude that it is feasible to assess therapeutic decisions through the application of
guidelines by a raearch team versus by an expert pane l. However, the decisions made
by the expert panel were used to assess the appropriateness of physicians' therapeutic
decisions . Of the four druB categories analyzed, the oVel'\Itilization and underu.tilization
rates were : proton pump inhi biton 12 and J SV.; H2 receptor antagoni sts 22 and 14%;
antibiotics 3 and SS·""; and prolrindics 8 and 0% respectively.
The second study invcstigaced infectiOD-fdated illnesses and the utilizati on of
antibiotics by four famil y physicians. Two panelswere invo lved in assessing the
necessity for antibioti cs and appropriumcss of choice, using the Ontari o Ant '--injecr ive
Guidelinu f or CoffUPQUJjt)'-<JCqWreJ Iflj«:tiOllS ( 1997). Paticn l inlerview s .....ere
perfonn cd and the congruency berween pajem and physicians' description o f primary
symptoms was 90"1.. Ofthe 98 patients inc luded in the assessment, 22 were prescribed
an antibiotic. \\'hen compval to the expert panel ' s decisi ons !he subsequent application
of the guide lines to the physicians' 1rcatment deci sions by a research tearn was highl y
sens itive and specific regarding the necess ity for antibioti cs but Ihere was less agreement
regarding the appropriateness oflbc type of antibiotic prescri bed.
We conclude from both stud ies Ihat it is feasib le to collect patient specific data from
physicians sufficien t to assess therapy using a research team venus an expert panel and
for the research team to jud ge prescribing appropriateness by applying expl ici t criteri on-
based guidelines . As a result ofthesc pilot studi es., two studies were designed to identify
inappropriate presaiption in the commWlity, and to assess the impact of educational
interventions on impro ving the prescribing practices o f family physicians .
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CHAPTER I
latroduction
1.1 BACKGROUND
The heal th care system is one of the moSl iDtcgm and important components of
society today. Thi s syst em is dwtging in order 10 accommodate the fluctuating
eco nomic $taNS or lhis country. Canad ians value the impressive level of health cart' lhat
has been provided to them over-the years and regard the wUversal iry and accessibil ity of
the Canadian health care service as a major adv 8nta ge ofliving in Can ada .
Canada has the seco nd most expensive health care system in the wo rld. In 1996.
health expenditures represented approximately nine percent of Canada's gros s dom estic
product (GOP) which is second only to the almost 14 percent oroop spen t in the United
States. J On a provincial level . in 1996 , Newfoundland and Labrador spent twenty -four
percent a f the provincial budget on health c:aJe.! Because of these large ex penditures and.
budg etary de ficits, vari ous anempu ha ve been made by al l Canadian govcmmen t to
reduce expend itures in heal th care.while striving to majnWn and enhance the quali ty of
heal th services that are available to Canadians.
The go vernment of Newfoundland and labndor in 1996 alloca ted S53 million
towards payment for phannac:eutica!s by individuals drug subsKlization in 1996 .1
Howe ver, in Canada, and olhc:r counbies., a substantial proportion afthe prescribing of
pharm aceu tical s is nol consi stent wi th criten _ for _ppropri_t e. safe and effecti ve heal th
care .' Dru g therapeutics is a rapi dly chan ging area of med ical care and it may be a facto r
that co ntributes to this inapprupriate presmbing by ph ysicians .
Various methods have been dev"dopcd to measure the Clt mt of ina ppropriate
prescribing by physicians and to imJWOvc these praaibing patterns. Dru g utilization
revi ew is a means of dctcnnining the incidcncc ofinappropriale prescribing within a
comm unity . As the~ to contro l health care costs is increasing. this method is
beco m ing more prevalentlhroughout the country . The widespread use ofdrug utilizat ion
review is attributable to the Ocltible and ubiqui tous nature of this process. which is used
to assess unnecessary care among physicians. phannacists and patients .·
One method that hu been utilized to cunail the unsa tisfactory prescription of
pharmaceuti cals is the development and implementation of clinical peseece guidel ines .
Anempts have been made to change physicians ' prescribing beha vior through the
U1il ization ofc:cru.i n guidclines and moderat e successes have oa: uned .s • The feasibil ity
of usi ng sudl gWdelincs sbouI d be determined before they ~ imp lemented as part of an
ed uca tional intervention. to cnhanc:e the probabil ity o f their SUl:CCSS in changing
prescri bing patterns.
Provincial govanmmts have made an empu to mod ify the uti lization of
pharmaceuticals within the ooun uy large ly through the imp lementation off'R$Cliption
drug fonn ularies or a restri ctive list on the type and price of dru gs paid for . The financial
pressur e of prescription druB plans on both private and publi l: punes is not only a
Canad ian problem but also a global phenomenon. It is seen now that cost containment
strategies like the fonnularies are minimally effective in restricting the rise of
expenditures. Governments are now turning to uti lization intervention to max imize the
effectiv eness ofpharmaceuticaJs while minimizing dollars e:xpended . Ifutilization
measures are adopted. physicians will need to agree to this interventioni st approach or
face economic press ures that will impede their ability to prescribe what they think should
be prescri bed .
Most provin cial gcvemmems in Canada pay a proporti on oftheir resid en ts ' drog
costs . Residents of Ontario, for exam ple, who are : (I) 65 years o f ege or older . (2) in
special care hom es or (3) under 65 years of age and eligible to recei ve general welfare
assistance. family benefits. extended health care benefi ts. or hom e care:benefi ts are
covered by the Ontari o Drug Benefit Plan for prescript ion drug s. However . in Onlario in
1992 total expen ditures for the province 's Drug Benefit Plan wou ld exceed one billion
doll ars. It is seen that various factors contribute to financial stress including the increase
of the elderl y popul ation. newer and more cos tly drogs and exten d ed paten t protection for
prod ucts, which limits generic substitution.'
A modification of provincia l drug plans in Canada is inevi table due to the presence of
financial press ures . Stakeholders in the health care system. howev er. should not lose
sight of the fact that prescripti on drug s are central to modem med ical therap y. The
benefit and well being of the patien t should be a critical component in considering change
to provi ncial drug plans by ensuring that therapeuticall y safe and effecti ve drug s are used
appro priately.
This chapter-describes and discusses ( I) how drug utilization can be assessed; (2) the
advantages and disadvantages of implementing different programs 10 improve
inappropriate prescribing patterns; (3 ) the feasibility of using criterion-based gui delines to
det ermine the optimal choice of therapy ; and finally (4) the effectiveness o f vario us forms
of interv entions.
Chapters III and VI discuss two pilot studies which were performed to determine the
feasibili ty of (I ) perfonning dnIg utilization review in the commun ity, and (2) compari ng
prescri bing patterns to cl inical practice guidelines . Co mmunity-based general
practit ioners were chosen as the study population in both studies since in Canada it is this
group of physicians who write thevast majority ofthe 230 million prescrip tion s given out
annu al ly.' In addition most studies , which have evaluated prescribing pattern s of
physicians have used hos pital-based physicians who prescri be under very different
circums tances . The drugs chosen for our investigation are upper gastroin testin al drugs
and anti biotics. These drugs have proven efficacy when used appropriately .
Th e purpose of these pilot stud ies was to determine whether it was feasible fo r a
researc h team 10 apply criterion-based guidelines to patient data and assess the
appropriateness of physicians' prescribin g patterns . These pilot studies aimed to guid e
the development of larg e-scale studies that could identi fy the extent of and reasons for
inappro priate prescribing in the communi ty and the impact thai interventions would have
on impro ving physicians ' inappropriate therapeutic decisi ons . The protoco ls for the
interventio n studies will be discussed in append ices E and L.
1.1 APPROPRIATE PRESCRIBING BEHAVIOR
Eddy ei al , (1988)9 stated that the appropriateness ofa particular practice is ascertained
through two steps. Firstly, a combination o f the available empirical evidence and clinical
judgmen t must be evaluated to assess health outcomes based upon the effect ofthe
practice. Secondl y , a comparison of the practice's favorable and harmful effec ts must be
made to determine if the benefit surpasses the harm.
Lavis et aI. (1996)'0 viewed the concept ofappropriateness as two distinct theori es :
(I) appropriateness of a service and (2) appropriateness of the setti ng in which care is
provided. The appro priateness of a service is whether a particular patient is expected to
benefit from a service based upon symptoms. physical findings and results of diagn ost ic
tests. The second theory is associated with cost-effectiveness. whereby this
appropriateness is determined by whether the services needed by a patient, based on their
clinical attributes. correspond to the setting in which the service was del ivered . The term
-sening' refers to a prox y meas ure of the reso urces utilized to pro vid e care.
The measurement o f appropriate provision ofa service and ofthe setting in which it is
provided. Involves the review ofa patient ' s medical record to obtain a complete clinical
history. This information is compared with explicit criterion-based guidel ines to
determin e the severity of the illness and the resources required to provide optimal
thera peutic care. The criteri a used for determining the appropriateness of a service are
primarily specific to a diagnosis or procedure. It is the theory ofappropriateness of a
service that was measured in the pilot stUdies that are discussed in Chapters III andV.
1.3 IMPROVING PHYSICIAN PRESCRIPTION: BACKGROUND
Guidelines and interventions to improve prescribing behavior are closely linked to one
ano ther. The acceptability of criteria is relative to the success of the intervention. such
that if an intervention is associated with penalties of any type (e.g .• restri ction of
pres cri bing ) gu idelines must be sound for the intervention to succeed . Furthermore . the
optim al util ization of any guidelines will require ongo ing. critical reexam inati on or
follow up imervennons.!'
In 1994 . the Effective health care series published IIcomprehensive survey of
international experience with theuse ofclinical guidelines. The authors revi ewed ninety-
one cl inical trials and they concluded that the introduction ofclinical gu idel ines can
indeed change clinical practice and affect patient outcome. Furthermore. how these
guide lines are de veloped, implemented and monitored influen ces the likelihood o f
adherence by physicians. 'l
The increasing sophi stication and cost of prescripti on therapy has necessitated the
development and implementatio n of interventions that are aimed at impro ving the
prescri bing beh avior of physicians . However. there is no systematic approach to
determi ne which intervention s are effective, ineffective, and which may even be hurtful. 'J
By ed uca ting physicians in the commwtity on the recommended treatment regime
outlined in the guidelines. it is possible to see a significant improvement in the
appropri ate prescription of drugs . A meta-analysis of studies. which evaluated the
effectiv eness of clinical guidelines. demonstrated that all hut 4 ofthe 59 stud ies that were
includ ed dem onstrated a signifi cant improvement relative to panerns of care prior 10 the
introducti on of the guidelin es . Thus. it can be concluded that cl inical practi ce can be
enh anced through ph ysicians ' adherem:e to explicit criteri on-based guidelin es .
'
The fonn of interven tion that has proven to be m ost effectiv e in enh anc ing physician s '
prescribin g behavi or , is one involving face- to-face visits with a pharmacist or physician .
Through these meetings the physician becomes involved in an interactive educa tional
exchange. In the follo win g stud ies it was shown that interventi on s invo lving only prin ted
ma terials, either given or mailed to the partjcipating physicians , had littl e or no impact on
the prescribin g behavior ofparti cipating physi cians.
Avom et aI. (1983)1. and Schaffner et al. (1983 )ISinvestigated these different form s of
intervention. The ph ysician s who were inc luded in these stud ies were se lected based on
Medicaid prescribing data . Avom et aI. used a ' face-to-face ' and ' pri nt only'
int erventions in their study of antibioti c prescribing beha vior, Th e latter form indu ced no
s igni ficant improv em ent, as opposed to the face- to- face intervention, which was proven
to be effective by reducing the prescri ption of co ntraindi cated drug s by 14% as compared
to a contro l group (P = 0.000 1).1. Schaffner et al included three form s of intervention _
ma iled brochures , vis its 10 doct ors by a tra ined phannacist, ' drug educator ' , and also
visits to doctors by a trai ned ' physician counselor' . Thi s study showed tha t an
improv ement in the appropriateness of physician s' prescribing beha vior was associated
with visits by a peer physician , which may be attributable to the messenger appearing 10
be more imponan l than the message .ISThi s form of interv ention prod uced stro ng
attributable reduction in d1enwnber of prescriptions written per doctor (AR = 54°1.; P -
0.000 1).
The interventions used in the proceeding studies involved a sequence of phases that
addressed different forms ofeducational methods. The intervention utilized in the De
Santis er aJ. (1994)'6study was initiated with mailed brochures, followed by a visit from a
project pharmacist who assumedthe role of an 'academ ic detailer' . Finally, additional
mailings were:sent to the physicians in the intervention group reiterating the brochure
messages. Although the results demonstrated the intervention group as having an
improvement in the pen;entage of prescriptions consistent with the recommended
guidelines there was also a comparable improvement seen in the prescribing patterns of
the contro l group, 60.5% to 87.7% and 52.901.to 71.7% respectivel y. This demonstrates
how adherence to various rec:ommendations may be directly related to who is performing
the academ ic detailing .
In contras t, the interventions used in the Gutierrez er al. (1994)11and Ekedahl et aJ.
(1995)" studies did not include personal visits by an ' academ ic detailer' to the
participating physicians . The Ekedahl et a1.study involved problem oriented group
meetings followed by a general group meeting that addressed certain objectives.
Although, the results of this study demonstrated a positive change in the prescribing
attitudes of panicipating physicians the reliab ility of the study could not be determined.It
Similarly, Gurierree eeaI. began thei r intervention with a training workshop , which was
followed by peer review group meetings. Assessmen ts were performed during the
intervention and throughout the follow up period, however, the reliability of these results
could not be determined,"
Other OUR interventions include an intervention that is executed when the physician
writes the pr-escription. or an intervention that occurs at the point of dispensing by the
phannacist. The fonner is the futuristic approach where the physician writes
prescri ptions on a computer tenninaI. Through the use of computer system s. clinical and
prescriptions data will be readily available and enable the physician. pharmacist and
decis ion software to be linked to the same infonn ation loop. This intervention will allow
the prescriber to be aware of drug~g interactions, drug-disease interactions and
whether or not they are presaibing appropriately. An intervention that is carried out at
the point of dispensing is the form ofOUR that exists today. This involves the
pharmacist screening the medication profile of the patient. By doing this they may be
able to detect any drug-drug or drug-disease interacti ons that may be apparent and
therapeuuc duplication or potential fraud and abuse." As this is a modernistic form of
OUR there is IinJe literature available thaI is aimed at assessing the effectiveness of this
method orDUR in detecting such interactions.
1.4 GUIDELINES
The core e lements of drug utilization review include evidence and criterion-based
guid elines; accurate patient specific data; and reproducible app lication of gu idel ines .
1.4.1. G uidelines alld Q uality Asl uraa"
The C anad ian Healthcare Association (CHA) has adopted a definition for cli nical
practic e guidelines (CPGs) from the lnstituteofMedicine in the United States. It stated
that e PGs are "systematical ly developed statements to assist practiti oner and patient
decisions about appropriate heal th care for speci fic clinical circumstanc es"," It is
assumed that through the imp lementation of these guidelines the overall quality of health
care will be enhanced.
Quality as surance confers a plausib le guarantee that the optimal standard in the quality
of health care is provided and it is thro ugh this process that problems in a physician 's
practice are detected and corrective measures are insti tu ted. Therapeutics is an area
where certain standards need to be met. The regular use of clinical practice guidel ines is
similar to quality assurance programs in their goa l to minimize clinical uncertainty,
reduce inappro priate variation in physician practice: patterns; while at the same time
enco uragi ng experimentation. and relying on sowxl measurement,"
In drug utilization stud ies, therapeutic guidelines provide a set of standards against
which physicians ' prescri bing patterns can becompared.I t It is recognized that criterion-
based guidelines are usual ly based upon two or three vari ables or a sole diagnosi s, and
that the application of these guidelines is affected by acceptable deviatio ns. However,
10
certain databases m ay not contain the variables that are necessary for the decision -making
proc ess in determining drug prescription appropriateness. The more patient specific the
data necessary to apply optimaJ therapy criteria, the less likely that these data will be
avai lable from government drug plans or other previously mentioned registry-based
so urces . This will vary from drug to drug , such that a review of a go vernment database
wi ll identify elderly patients who shouldn't be taking certain drugs ,l l whereas thi s
database would be inadequate Codetermine theappropriateness of antib iotic utilization .
In the latter instan ce il co uld be argued that phys icians ' recordsmay not contain enough
infonnation to determine appropriateness and that patients needto be interviewed to
acc ura te ly determine which sympt oms were present.
1.4.2 . Utillz . do ll of G uid dbln 10Alsns Ph yl lclaal t Pnctke
Yu et al. (199 1rz assessed the antibiotic prescribing habits of physicians. A consensus
panel con sis ting of a chi ef medical residen t, an infectious disease physician, and a cli nical
pharmaci st developed a clinical grade of appropriateness that served as a " gold stan dard" .
Th is panel evaluat ed the appropriateness of an antibiotic selection for 78 consecutive
pat ien ts and class ified 34 .6% as inappro priate. The infonnation that was ass essed
cons isted ofa physician interview , patien t 's medical chan and past med ical history, and
an y subsequent hospital course. This stud y theorized that clinical guidelines co uld be
utilized to assess phys icians' cl inical decisions, how ever , it was not documented in the
art icle whether or not the reliability of the guidelines themsel ves was assessed.
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In 1995 , Donnell y et al. 12 conducted a pilot stud y where clinical guidelines were used
to detennine the appropriateness ofpatient placemenL Subject: selection and data
co llectio n methods used by Donnelly et aI. differ from the pilot studies discussed in
Chapter III and VI of this thesis, yet all studies are similar in their application of criteria
to assess the appropriateness of clinical decisions . A multidisciplinary consens us group
defined criteria for admi ssion to Intensive and High Dependency Care Units. as publ ished
guideli nes were not available. Appropriateness of admissions was detennined by
meas uring actual perfonnance against the criteria set for admissions. These correlations
demons tra ted that the rate of inappropriate placement in Intensive Care Unit was low (0 -
10"/0) whereas the rate in the High Dependency Care Un it was as high as 82%. Donn ell y
et al. (1995) co ncluded that it is feasible to assess the appropriateness of patient
placemen t through the use of professionall y derived guidelines; demo nstrated that it was
feasible to generate the data necessary to assess the appropriateness of clinical
decis ions."
Figure 1.1 swnm ari zes the approach taken by an expert panel when applying the
guide lines.1) Thi s process for ascertaining whether the patient's physician made the
optimal therapeutic decision is a very lengthy process . It is difficult to assem ble the
expen.s in a panel and time conswning to assess the treatment for every patient. The two
pilot studies repcrted in this thesis assessed the utilization o f drug s for upper
gastro intesti nal diseases and antib iotics . They involved 6 physicians (84 patien ts) in the
former study and 4 phy sicians (99 patients) in the latter one . The protocols for the larger
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scale studies derived from the pilot studies involv e the recruitment of appro ximatel y 80
physicians and over 1200 patient charts . Based on a study that was perfonned using an
expert panel review 2' , it was hypothesized that to use an expert panel for a OUR of 1000
patients could take 50 hours . which is a large amount of time for bus y physicians and
pharmacis ts. Therefore it would be very di fficult to assembl e an ex pert panel 10 asses s
over 1200 patien t cases as proposed . Conseq uently. this study can be co mpleted much
more efficiently if the researcher can apply guid elines with out the use of expert clin ical
j udgmen t can appl y guidelines. By hypothesizing this it was necessary to determine the
feasibility o f a research team using explicit criterion-based guidelines to assess a family
physician ' s therapeutic decisio ns.
Figure 1.1: Appliatioa of CriterioD-Bued GuideliBes
I .S DRUG VTlLIZATION REVIEW
Drug util ization review is defined as an adaptable processin which predetermined
criteria arc used 10 assess the quality andcost-effectiveness of (I) drug prescription by
physicians: (2) drug utilization by patients; and(3) drug dispensing by phannacists ..l' 16
Curren t infonnation, case-based criteria and clinical practice guidelines arc consolidated
to establi sh explicit aitcrion-bascd guidelines , which an: then used to measure the quality
of thcra peutic decisions made by phys icians. Th is assessment is best achi eved thro ugh a
pro cess known as drug utilization review.
Dru g uti lization review (DUR) is a form ofassessment in use for more than 20 years.
Throughout thi s time considerable research and commercial endeavors ha ve contributed
10 the fonnation of an ex tensi ve knowledge base which can be applied to question the
ap propriateness ofdrug utilization. During the late 1960's and earl y 1970 's, OUR
appeared to focus primarily on drug interactions andoveruse of regulated dru gs.
Subseq uently , OUR has been. expanded due to the recogni tion ofother pot enti al pro blem s
with drug s, such as incorrect do se or dUl1l.tionof prescription. and drug-induced diseases
(e.g .• antibiotic resistance)."
A relatively broad definition of OUR has existed since its evolutio n. Thi s definition
includes analysis of various aspects of prescription and dispensing patterns among both
physicians and pharmacists, and implem enting programs to monitor and control improper
patterns in particular settings. These OUR programs incorporate "knowledge.
understanding, judgments, skill s, constraints, and ethics" into the review so that the
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optim wn prescription and usc o f mcdications is assured while at the same time improving
the qual ity o f druJ tbenpy and c:ontrolling pharmaceutical ecse." Jl Althou gh thi s broM'I
co ncept has had good results. some problems bave also been outed. Favorably, it has
created a broad arena foe' the deve~pmcnt ofmmy inno vative approaches to improvi ng
drog usc . However, this outcome generated an Q pectati on that a "gold standard- of
appro pria te drug utilizatioo cUstS. Even if a "gold stmdanr" did exist, it is DOtclear that
it could be met despite optim al information, education, andbehavior of prescribing
physicians . pharmacists. and patients. This is likely because we do not live in I stati c
environmen t and the dynamic and highly competitive intern ational pharmaceu tical
mark et creates a major challenge to achieving the optimaJ utilization of drug s.II
There fore, it has beensuggested by Barber (1995) to define whalt physicians should be
trying to achieve whenprescribing rather thantryin g to define what consti tutes good
prescribing. In Bather 's model it is illustrated that the ph ysician should strive for four
object ives to attai n good prescribing habiu : (I) maxi mize e ffectiv eness; (2) minimize
risks; ( 3) m inimize costs; (4 ) res pect the patient 's choices. n
Typically, the purposeof dNg uti lization review is to ensure that only patients who
require dru gs get chcm. A 101: o f emphasis has been. placed on red ucin g inappropria te
overu ti liza tion of phumaceuticaJs. where patients who do not need drugs receive them .
Howev er, the undeNtilization o fmedieation, where patients who need drugs do not
recei ve them, is of equal importanee.29 Not only must the correct choice of medication be
administered, but the prc:scribed dosage and duration of medication must also be
appropriate. This approprialeness of prescription is based on pharmacckinetic
considerations. concomitant medications, comorbidities, and other risk factors peculiar to
theindividue.l.
Phannacoeconomics is anothel"Conno f OUR that has been defined as "the descrip tion
and analysis of the costs of drug therapy to health care systems and society~. Jo
Phannacoeconomic research involves the measurement and comparison of tile costs of
pharmaceutical products and services . Inherently, this form of analys is expl ores the
impact (both beneficial and nonbeneficial) of alternative drug therapi es and other medical
unervemicns to achieve optimal and cost-e ffective utilizati on ofphannaceutical drugs.
1.5.1. Vrillzatioa of EspUcit Criterioaoobated GuideUaes for DUR
The implementatio n of a OUR program to determineif a physician has mad e the
optimal diagnos tic and therapeutic decision involves the appl ication of ex pl icit cnterien-
based guidelines by a researc h team , an expert panel and/or a computer sys tem . In
addition to the explicit cri terion -based guidelines the latter panel may also uses clinical
judgment. i.e. implici t criteri a, to determine the appropriateness of treatment prescribed
by the physician .
It is argued that clinical freedom , innovation and individual case discreti on are
restri cted through the use of clinical guidel ines .J1 However, there is evidence that
guidelines provide long -term benefits by increasing the level of health care" and
contro lling cos ts." Unfortunately, successful implementation of guidel ines co ntinues to
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be a formidab le obstac le.J.o An interven tion may be implemented to ensure that these
gu idelines are communicated properly and to the appropriate peop le.
1.5.2. De"e lop meat of Crlterloa-bued GttideUlln
Criteria are predetermined clements against which the quality and econom y of drug
use are judged. It is these crileria whic h represent the ideal to which aetual drug use is
compared . They must be useful. effiaent and relevant to the outcomes that are being
measured . Criteria that are clinically and scientifically grounded provide a foundation
from which clinical guidelines are developed. Computers use guide lines to screen
millions ofprescriprions npidly and therefore, guide lines musl beexplicit and capabl e of
reduction to sim ple rules for initial application. The prescribing. dispensi ng. and patien t
compliance o f a pharmaceuti cal agent are involved in the assessment of appropriatenes s.
where empirical data and application of criteria may be used to identitY "no rms" abou t
the appropriate pharmacological use of a prescription drug .JS
The criteria upon which the guidelines are based may be either implicit, where the
criteri a are based on an indi vidual 's expert judgment, clinical experience, and knowledge
ofltterarure, or they may be expl icit, where compendia, texts and literature form the basi s
upon which these criteria are devel oped . Although implicit criteria involve clinical
experience and expert judgment, this approach does not yield results that are as
reproducible as those obtainedthro ugh the utilization of explicit criteria. The explicit
criteria approach may be more consistent and reliable in its finding s. regardles s ofwho
applies the criteria. However, thi s approach does not include the complete assessment of
"
an individual patient. Since the utilization of pharmaceuticals is very complex. a
conver gence ofbotb implicit and uplicit criteria could be the optimal steategy." A
com bination ofthese criteria would provide the basis for criterion-based gu idel ines.
In order to develop and maintain credible criterion-based guidelines. it is necessary
that they be based o n generally acclaimed litc:ranue that is scienti ficall y and clinically
gro unded. Cri terion-based guidelines used in clinical practice are cons idered technicall y
valid if they lead to cost-effective clinical practice. improved patient outco mes and
q uality ofhea1th cere." Not only must the criterion-based guidelines be technically val id
and reliable, they should be accepted by the appropriate experts, academic. clin ical and/ or
industrial . and the subjects that are beingevaluated through that OUR program must also
perceiv e themas vaJid .2lI Once the reliability andvalidity of theexplicit criteri on-based
cri teria has been proven, both the guidelmes and their rational e should be made available
to all physicians .
1.5.3. Perform.ace of DUR
Brater et al. formed a panel that determined the information necessary to perform a
OUR J1 (Table 1.1) .
"
Table 1.1 : IIIformatioD Required to Perform OUR
Drvg Utiljzati on Review Information
I. Patient characteristics Age and birtbdate
Sex
Weighl and Height
DnagalJergies
Specific diagnoses and. when relevant, an estimate
ofdisease severity
2. Drug data Chemicaimtity
Dose 1_........ &cqucn<y)
All medications the patient is taking. including
over -tae-cocnter products
Longitudinal history of dtug intake
3. Health care uti lization Hospitalizations and Emergency room visits
Office visits
Nursing home use
Home health care
The inform ation that is mentioned above allows for various endpoin ts relating to drug
therapy to be assessed . The following endpoints are relati ve to the objectives of the pilot
studies descri bed in Chapters mand V:
I. Noncom pliance - patient does not take medication as directed [i.e . dose. durat ion or
frequency ).
2. Overuultzauc n - frequency ofpatien ts who did not need a class of drugs but received
3. Underuti lization - frequency with which patien ts tha t needed a class of dru gs did not
receive them .
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1.5.4. Forms or Drul UtillzatioD RevieWi
There are two types ofdrug utilization review, registry-based and patient-based, and
two manners in which these reviews are performed, retrospectively and prospectively.
These forms of OUR differ in the source of infonnation and the manner in which the
necessary infonnation about drug use is obtained. There are advantages and
disadvantages to each type.
1.5.4 .1. Regjstry and Patient·Based Review
Registry-based
The prescribing behavior ofphysicians is inadequately measured through self-
reporting, which has led researchers to use registry-based prescribing records, that is
national, provincial or statewide administrative claims databases . to assess changes in
prescribing behavior." Medicaid databases have proven to be very effective and allow
for efficien t and cost-effective studies to be performed on dJug and health care utilization
in the United States ." I' J9.o However, this information is generally in a crude statistical
form for the purposes of paying claims and does not confer details relative to the patien t
and the conditions for which their individual physicians prescribedmedication.
Moreover, it is very difficult to obtain information concerning the use of ever-the-counter
(OTC) prepan.tions by members of the comrnwrity through registry.based data.
Retrospective rcgjstry-based reviews audit both pharmacy and medical claims data .
Through this analysis inappropriate patterns and trends pertaining to various prescription
drugs and physician prescribing practices are identified" and this type of review also
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pennits the maximwn amoun t of information, for a large nwnbcr of patients, to be
obtained at a minimal cost." However, the infonnation that is obtained in this manner is
limited and should not be used to make inferences concerning the general population.
Such registry -based databases are not designed for research and in the absence of
diagnostic information the results obtained from this secondary data wi ll co ntain inheren t
error and bias . An inhcrc:nt bias may be pn:smt in a stud y population tha t is involved in a
registry-based review . For exampl e, a Medicaid prescription claims database lists
prescripti on drugs used by thepoor andthis population docs not represent the general
population.
Prospecti ve patien t-based drug utilization review s use systems that enabl e the
research ers 10 detect a problem before the pharmacist dispenses the prescription .
Although this fonn of OUR is beneficial in the detection o f potentiall y dangerous drug -
drug interactio ns, therapeutic dupli cation 01" abuse, andexcess ive prescribing behavior , it
is agreed that this OUR would not address problems o f inappropriate dosa ge, duration or
incorrect prescribing. There is very little literature pertai ning to the utiliza tion of these
reviews as they require extens ive and complicated software programs and, although they
may playa useful role in improving prescription drug use, their use is limited.~
Patient-based
Patient-based D UR is a tedious and costl y method to docwnent chang es in physicians '
prescribing behavior, which involves a thorough review of each patient 's chart . Thi s
fonn of OUR examines the drug therapy that is prescribed to individual patients and then
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assesses the appropriateness of prescription by measuring against predefined criterion-
based guidelines. The advantage oflhis retrospective Conn of review is that., in addition
10 the patient 's chan providing the information that is necessary 10 accurately assess
physicians ' prescribing behavior, the review can correlate drug prescription to the age.
sex. employment, social status, or disease of patients. Unfortunately, where such records
are made available for review it has usually been on a modestscale and the physicians
who consent 10 participate may be specially motivated pbysicians whose prescribing may
not be characteristic of thegeneral population.G Furtbmnore, there are only a limited
number ofCanadian studies that have assessed this method of OUR. A meta-analysis
performed by Einarson et al. involved sununarizing the results of JJ articles that utilized
cri teria for identifying drug therapy appropriateness, which were based on expert opinion .
10 evaluate drug prescription. The average rate of inappropriate prescrib ing overal l was
43%. which included drug indication., choice ofdrug. and drug administration (dose .
durat ion or roule) . How ever . the greater part of these studies assessed prescribing
patterns in a hospital setting as opposed 10 the prescribing patterns of community based
general practitioners."
Despite the fact that these prospecti ve OUR computer systems have existed for over
15 years at the pharmacy level , they are practically nonexistent at the physician practice
level. However, as more physicians' offices become equipped with computer systems,
the probability of incorporating prospective drug utilization review s that will influence
the physician 's decision before the drug is prescribed will Increase significantly . The
13
most successful prospective DUR prognm acts as a remoder and alerts the physician of
any discrepancy when hislher prescribing is compared to optimal practice .se
The two pilot studies thai are discussed in chaptm III and VI implement the
retrospective patienl·based fonn ofDUR. This involves using pre-determined criteria to
crit ique the utilization of drugs after physicians have prescribed them . This type ofdrug
utilizati on review genaally coocentratcs on preventing a rcoccurrence rather" than deal ing
with an imminent problem . Although it is a very ledious and costly method it has been
argued that retrospective patient-based DUR is the most feasible and adaptablc approach
to obtai n accurate patient specific data and.unlike the majority of registry-based DUR..,it
does notlitnit the patients being assessed to those who are using administrative claims
databases . In order to ClISUI'e that optimal resulll'l are obtained precise definitions and
anal yses o f what constitutes inappropriate drug use must be applied to the data .
"
1.6 SUMMARY
The health care delivery systenl is under intense pressure to contro l costs . Recent
evidence indicates that in Canada and other countries a substantial proportion of
prescribin g practice is inconsistent with criteria for appropriate health care.J It is this
waste of limited health care resources that makes it necessary to enhance drug utilization
review. Drug utilization may be reviewed through govemmcn tlprivate drug plan
databases , however , the appropriateness of therapeutic decisions may be best achieved
through the application of explicit oitmon-based guidelines usinBpatient based OUR.
The purpose of both pilot studies reported herein was to test the feasibility ofa research
team applying criterion-based guidelines to accurately assess the therapeutic decisions
made by a family physician, i.e. patient-based OUR. Drugs for upper gastrointestinal
diseases and antibiotics were assessed .
A review was perfonned on literature pertaining to (I) uppe!'" gastroinlestinal disorders
and their optimal treatment ; (2) epidemiology of upper 01 disorders ; (3) utilizat ion of
antibiotics; (4) prevalence of antibiotic resistance ; and (5) using criteria to assessthe rate
of prescription and the appropriateness oftherapcutic decisions made by famil y
physicians . The articles reviewed in Chapters II and V, in addition to those penaining to
the efficacy of the various classes of drugs, enabled explicit crileria to be developed for
these studies.
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Throughout these studies the following quesnoes were asked eo determine the feasibility
of using explicit aiterion-based guidelines to assess the appropriateness of general
practitioners" prescribing patterns.
CHAPTERU
Utilization of Dngs for Upper GI Disorden
l .t DRUGS FOR UPPER GI DISORDERS: LITERATURE REVIEW
There is a lack of literaturc pertaining to physicians ' prescription of upper
gastro intesti nal (V G£) drugs although there is an abundance ofIi terature associ ated wi th
UGI disorders and the efficacy ofvarious types of treatment . Although upper
gastro intestin al disorders are common in today's society , the actual frequency of thesc
disorders is underestimated considering that peop le often treat lheir symptoms with over-
the-counter medications, rather than report them to their physician.
2.1.1. UtillzatioD ofUpperGIDnp
There are few studies that have used criteria to determine the rate and appropri ateness
of upper gastro intestinal drug prescription. One study was published in 1990 but is now
outda ted since newer drugs have been appro ved for the treatment of gastroesophagea l
reflux disease , nonulcer dyspeps ia and pepti c ulcer disease."
Acco rding to Raisch et al (1990)" the mean rate of histamine (H l ) receptor antagonis ts
and sucral.fate for inappropriate indications rang e from 41.30/. to 52.1%. The criteria used
in this assessm en t were representative ofthe standards of pnctice within the communi ty
at that time. Subseq uent to these results other classes of drugs have been approved for
the treatment oftbese disorders. indudlDg proton pwnp inhibitors ± antib ioti cs and
prokinetics. No study has been performed to determine the appropriate uti lization ofall
currently available classes o f upper gastrointestinal drugs .
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The current treatment of upper gastrointestinal disorders invo lves six categories of
drug s; pro ton pump inhibitors (F PI) , prokinetics (Prok), histamine H~ recep tor
antagonists (H2RA). antib iotics (Abs), cytoproteetive agents., and antacids. These drugs
are efficacious when prescribedfor the appropriate upper 01 disorder. yeecan be futile if
used inappropriately. In the current stud y therewere DO prescriptions of cytoprotective
agents and antacids., so only the fint four lIIet1ts will be refand to in this thes is . (See
Appendix D for mechani sms and indications).
During I 99S, in Newfound land, tbc:n:were: nolimitations on prescriptions of drugs for
upper GI diso rders. By 1996 expenditures on proton pump inhibitors had become so high
that the N ewfound land provincial govermnent imp lemented a policy restricting their
provision by the provincial formulary in the absence of an explicitly justified request by
the do ctor. Although this was intended 10 be a cost saving measure, it ma y hav e led to
peopl e who needed proton pump inhib itors not being prescribed them . As a resul t.
inappro pri ate dnagsmay have beenprescribed in their stead, resulting in the
underu ti liza tion ofone class of efficacio us drugs and overu ti liza tion of other classes .
Recently, clinical practice guidelines were developed for the treatment of upper
gastrointesti nal disorders: dy spepsia. peptic ulcer disease andgastroesophageal reflux
disease . These guidelines were jointly developed by NewfOlmdland and labrador's
Departm en t of Health, Medical Association and the Newfoundland Pharmaceutical
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Association. as well as members ofScbool of Pharmacy and Faculty o f Medicine. These
guidelines provided a foundation for the criterion-based guidelines that were used in the
pilot study that assessed the utilization ofupper gastrointestinal drugs . Appendix C gives
a more detailed description of tile infonnarion used to devel op these guidelines.
2.1.2. EpidemiologyofGI Disorden
A study of the epidemiology ofupper Gl disorders is encumbered by the lack of
physical markers for both gastroesophageal reflux disease anddyspepsia. A
measurement of the laner is further impeded by existing discrepancies pertairting to the
defin ition of lhis functional disorder .
Despite similar difficulties in the diagnosis ofpeptic ulcer disease . attempts have been
made to detennine the prevalence andincidence of this disorder. Perforated ulcers cause
patients to suffer a singular attack ofpain and shock which enabl es a prompt diagnosis.
however. the lack of symptoms associated with uncomplicated and bleeding ulcers
obsc ure their diagnosis.
Langman (19g5)" ' referred to the attempts that were made to establish the point
prevalence of peptic ulcers . This included an endoscopic survey of358 nonnal Finnish
subjects. which revealed duodenal ulcers in 1.4%. Drossman et al. (1993)""perfonned a
household survey in the United States that found the annual prevalence of peptic ulcer to
be 1.6%. However confirmation of the ulcers was unattainable and "silent" ulcers were
not detected . Various studies indicated a 10-;" prevalence of peptic ulcer with a point
prevalence of 1-2% in developed countries. Acc::ordingto Thompson (1996) the
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incidence of peptic ulcer is approximately 0.1% per annwn. In Copenhag en, Denmark
the incidence of duodenal ulcer in men was determined to be 0.1 S% and 0.03% per
annwn in women. Similarly, in Yorkshi re the incidence in men and women were 0.21%
and 0.06 % per annum respec::t:ively.u
Upper gastro intestinal functi onal disorders require a complete epidemi ological
reassessment. The reassessment is necessarydue 10 the emergence and discovery of the
bacterium Helicobacler py lori. The ubiquily ofthis organism is astonishing and most
hum ans are infected with H. pyl ori yet experience no syrnplOmS. Allhough. Roben
Koch 's (184 3 - 19 10) posIUlalcS q .. ~ are fulfilled for acute gastriti s, they have not
established H.pylori as a cause ofeither peptic ulcer or functional dyspeps ia. Signi ficant
evidence shows that non-NSAID ulcers occur where H. pylori is present. A review of 15
studies co ncluded.that 92% o f patients with duodenal ulcers are infected with H. pylori.u
Another SOW'Ce of peptic ulcer disease is NSAID use with a point prevalence o f 15-
30"/0in chro nic NSAID users . The ideal treabncnt for these ulcers would be the
disco ntinua tion of the offend ing agent. Yet many patients are unwilling to forego the
relie f of pain and inflanunation provided. by NSAIDs." Due to this unwillingnes s it is
necessary for a prescription of proton pwnp inhibitors, which are more effecti ve than H2
receptor antagonists in the treatment ofNSAID induced ulcers .J;l n ~ "
CHAPTER III
Uti1lzadoa Review of Drugs for Upper GI Disorden: Pilot Study
3.1 RATIONALE
Restri ctio n of access to proton pwnp inhibitors through the Newfo undl and and
Labrador Drug Program could lead to underutilization of these efficaci ous agents and
overuti lizatio n of other less appropri ate drugs in patients with upper GI diso rders . The
pilo t study was undertaken 10 test the feasib ility of using criterion-based guidelines,
ap plied by a research team, so that current medical practice for upper G I diso rders cou ld
be asses sed . Thi s pilot studycollected patient specific information and compared the
diagnosi s and treatment provided by the fami ly docto r to that aCthe decisi ons made by an
expert panel , a research team and a trained research nurse . The criterion-based guidelines
used to make a diagnosis were based upon infonnation obtained from the literature and
clinical experts , based on symptoms ofgastroesophageal reflux disease, non-ulcer
dyspepsi a and peptic ulcer disease and the mechanisms of the drugs used to trea t upper
G I diso rders (Appendix C Ii D) .
Th e criterion-based guidelines for opti m al treatment of upper gastrointestinal disorders
were based primarily on the jointl y devel oped. Guidelines for Gastrointut;1lQ/
Conditions: Dyspepsia and Gastroesophageal Rejlux Disease.~ and the Canadian
Consensus Conf erence 0" the TreaPrrentofGastrouoplulgetJl Rejlu.:tDisease (/997).$1
Th e former guide lines arc suppo rted by an algorithm that was developed by Bnm
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(1996)." The criterion -based guidelines used in this pilot study are those accepted by the
Provincial Drug Progrmn and recommended. for usc in Newfoundland and Labrador.
3.1 METHOD
A patient based mrospective dJUg utilization review was performed using patient
chart and physician interview to obtain history and treatment of upper gastro intes tinal
diso rders . and the application ofme aiterion-based guidelines for diagnosis and
trea tmen t (Appendi x C and Fig. 3.1) to thesecases by (a) an expert panel .
(b ) a research team. and (c) a research nurse. 11Je research team consist ed.of a researcher
and a clinical epidemi ologist who pro vided content expertise support" to the researcher .
The schema used by all 3 assessors is illustrated in Fig . 3.1.
3.1 .1. D.ta ColJedioa
Diagnosti c and treatment da ta were abstracted from the patien ts' cham, usin g a
standard ized instrum ent (Appendix B). The past medical history of each pati ent.
incl uding concom itant medications and comorbidities. was obtained . Following th is data
co llection each physician was interviewed by a research nurse , which provided additi onal
info rmatio n and a verifica tion of the data collected from each patien t chan .
3.1,1. AppUClitioaofGllldelln"
Th e data collected. from each patient' s chart, using the abstracti on form (Append ilt B).
was revi ewed by an expert panel that was comprised ofa gastroenterologist, phannacist
and epidemiologist. Thi s panel determined the diagnosis and treatment necessary for
• CODICIlI cJtpertise support ~ren to • physician ' . elinical kDowledgc and aperimee
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each patient based on the infonnation obtained from their med ical record. The
appropriateness ofdiagnoses and treatmmt decisions made by the family physi cian was
determi ned by comparing them co the decisions made by the expert panel . The rate of
appropriateness ofthe treatment prescribed by each doctor was determined by the
frequency with which patients who needed a class o f drug s and did not get them
(und eruti liza tio n) and by the frequeDcy with which patients who did not need these drugs
received them (o verutilization).
Crilerion-based guidelines for diagnosi s and treatmmt were applied to each palient 's
case by the research team . Decisions made by the reseercber were compared 10 the expert
panel's decisions. Alas of disagreement were discussed and criteria were improv ed to
reach a consensus with the ellpert pando As thi s is a pilot stud y being used to ensure that
appro priat e and so und guidel ines are developed. the guidelines were improved during the
process of me study. A research nurse also appl ied the criteria who had no part in the
research project but who was trained in how to apply the criterion-based gu idelin es.
Criteri a used for diagnosis are shown in lable 3. I and the guidelines used for treatment
decisio ns are shown in figure 3.1. Criteria providing a funhcrexplanation ofthe
guidel ines for treatmmt, as deri ved fromconsensus o f the expert pand and litera ture. arc
shown in Appendix C.
ra
Table 3.1 : Criteria for DiapOIiI
Diaposis
Gastroesophageal Reflux
Disease (GERD)
Dyspepsia (nonulccr)
GERO! Dyspepsia
Peptic Ulcer Disease (PUO)
Symptoms
heartburn, acid regurgitation, retrosternaIpain, reflux
epigastric pain. upper abdominal pain. nausea.
indigestion. dysmotilityt
symptoms., past or pracnt, of GERD and
dyspepsia
symptoms of dyspeps ia wi th confinn ation of
gastric/duodenal ulcer (without NSAID use). seen on
endosa>py or barium meal, or inflammation of the
doodenal bulb (duod enitis)
t dysmotility symptoms ""gas. bloating. fullness
..
Figure 3.1 : Guldelia" ror Trntmeat of GERD. Dyspepti. ud Peptic Uker
D......
= H. py lori eradication therapy; Abs = Antibioti cs
"" adda PPI if severe heartburn is present
Legend :
LSMJOTC - Lifestyle mod ificati ons &Jor Over-ihe-counter medications
+ = sym ptoms present; - ,. symptoms not presen t
"
3.2.3. Etbics
The Hwnan Investigations Committee of Memorial University of Newfoundland
approved uus study. Patient consent was not required as DO procedure was perfonned on
patients . All physician and patient information was kept confidential. Nwnerical
ident ifiers , known to the researchers , were used to distinguish the patients and physicians
enro lled in the study . Phys icians were the focus of this study, and a research nurse made
initial contact . Infonnation was obtained from those physicians who signed a consent
fonn (Appendi x A) andagreed to participate in the study .
3.2 .4 . Siadstkal AaalyJlis
The data obtained from the st1Jdypopulation were analyzed with the Stati stical
Package for Social Sciences (SPSS). Dcsaiptive statistics were used to characterize the
physicians and patients. Cross tabulations were pc:rfonned to compare the dec isions of
the family physician, expert panel and the guidelines pertaining to the appropriateness of
prescript ion as applied by a research team and a research nurse . Where possibl e a
quadratic weighted kappa score was calculated to allow for a correction for chance
determinations of appropriateness. The quadrati c weighted kappa statistic was utilized,
as it is the statistic of choice for measuring agreement with ordinal data ." This form of
statistic is derived from the original Kappa statistic with assigned weights based on the
magnitudes of observational disagreements.eo
"
3.3 RESULTS
The results portion of this chap1er , I. describes the overall characteri stics of the
physic ians and the patients who were involved in the study; 2. i1Iustrates the resul ts
obtained when criterion-based guidelines are used to assess the prescribing patterns of
upper GI dru gs by family practiti oners . The latter section of this cha pter is divided into
four com ponen ts. The tim com ponent demonstrates the feasibili ty of using explicit
criterion-based gu idelines to mak e an accurate diagnos is and treatment decision . This
was accom plished by comparing the decisions of the expert panel to tha t of the research
team appl ying the guidelines , and to that ofthe research eurse . The seco nd component
assessed the fami ly physicians ' decisions, using the expert panel ' s decisi ons as the
accepta ble assessment tool. An evaluation of upper gastrointestinal diagnosis and drug
prescrip tion rates in the SL John ' s - Mount Pearl area is shown in the third component.
This eval uatio n is also based upon the judgements made by the expert panel. The last
component characterizes the appropriateness of drug prescription for upper
gastrointestinal disorders .
3.3.1. Pby sldaa ud PalXat Cbaracteristlcs
Six family physicians pani cipated in the study, 1094 patien ts were identified from
their bill ing records dwing a 6 month period and the IS most recen t patien ts seen by each
physician for upper Gl disorders wer-estudi ed. Children and pregnant women were
excluded . Patien ts with the following Medicare Plan (MC P) bill ing codeswere included;
"
Table 3.1 : MC P 8 lWal Codes
MCP Billing Codes
Code Diagnoses
530 Disease of the esophagus
53 1 Gastric ulcer
532 Duodenal Ulcer
534 Peptic ulcer , site unspecified
535 Gastrojejunal ulcer
536 Gas tritis and Duodeniti s
537 Disorders of funetion of stomach and duodenum
537 Dyspepsia
787 Dyspha gia
Patients included in the pilot study presented with the following sym ptoms! co nditions:
upper abdominal paint
disco mfort
2. upper retrcstemal pain!
discom fort
3. epigastri c pain
4. heartburn
S. gastritis
6. peptic ulcer disease
7. esopha gitis
8. problem s with the stomach and
duodenum
9. dysmotili ty
10. acid regurgita tion! reflux
11. dysphagia
Of the 90 patients revi ewed, 5 did not present with the abo ve upper Gl symptoms!
conditions , and one case provided insufficient data, resulting in 84 cases suitable for
analy sis.
"
Infonnation about the six physicians who participated in the study is shown in table
3.3. All physicians were in group practice settings that were located throughout the St.
John 's - Mt . Pearl region . Tben::: was. wide range in the nwnberofpatimts seen with
upper GI disorders by each physician within the six month period (range = 34 - 753).
Table 3.3 : Phy.lc:iaa CharKUrildcs
Physician 1
Physician 2
Physician]
Physician 4
Physician 5
Physician 6
Mol.
Mol.
Mol.
Mol.
Mol.
Mol.
Year Graduated
1975
1957
1977
1979
1991
1975
# Patients Seen •
60
34
83
414
153
290
• patients seen for upper GJ disorders within a 6 month period
Table 3.4 swnmarizes the characteristics ofthe 84 paticots included in the study .
Table 3.4 : Padent IbseUae Ckarac:ttristics
Patient B••eline Characteristics
(N -84)
Age-
M.",
Range
18 - 29 yr.
30- 44 yr .
45 - 59 yr .
60 - 74 yr .
~ 75 yr .
5..
Female
Male
Allergies
Penicillin
47.3 yrs
7 (8.3%)
37(44.1% )
19 (22 .6%)
17 (20.2 %)
4 (4 .8%)
32(38.1%)
52(61 .9"/0)
4(4.8%)
"
Within a six month period there was a total of 1094 patients with uppeI"GI disorders
(mean =182 ) seen by the six physicians. Oftbese 1094 patients 84 were inc luded in the
study. Th e mean age was 4 7 (range 18 - 83) years and the percentage of femal e subjects
was 38% (N =32) .
3.3.2. Fu51blUty of Vlml Gukkliaes Without AliiE:lpert Paael
3.3 .2.1. Diagnos is
A comparison of the expert panel andresearch team ' s diagno ses are shown in Tables
3.5 and 3.6. Diagnosis was based on symptoms, yet dyspeptic andGERD sym ptoms
frequent ly ov erlap or vary over time. Funbennore, the treatment for mild to moderate
cases of both GERD and non ulcer dyspepsia is similar and it was cons idered reasonabl e
to comb ine the two diagnoses into one category, GERDlOyspepsia (Table 3.6) . Cross-
tabu lations were perfonned on the data to report the percentage o f agreement between the
research ream and the expert panel and the Kappa sta ti stic was used on the data in table
3.6. A substantial improvement in agreemen t. 61% (95% CI =0.56 10 0.77) -. 100% (K
= 1.00), OCCUlTed when nonulcer dyspeps ia and GERD were cons idered ov erl ap d isord ers
(Tabl e 3.6).
...
Ta ble 3.5 : Co m parison or Diaposn I\b de by EIpert Puel ud Returc:h Tum
Rcsean:hTearn
pepti c Nonu lcer GERO GERD ! Insufficient
VI.,., Dyspepsia Dyspepsi a Data
Disease
Pepti c Ulcer )'
Disease
Nonulcer 23 13 7
Dyspepsia
Ex""" GE RO 2 17 ,Panel
GERO ! )
Dyspepsia
Insufficient 2 I
Da ta
Table 3.6 : Comparison or Dlaposn Made by E llpert Panel an d the Rn ea rc:h Tea m
Wben GE RD aDd Noa uker Dys pepsia are Considered Onrlap
Dlsorde"
Research Team
Peptic Ulcer GERD! Ins ufficient
Disease Dyspepsia Data
Pep tic Ulcer I'
Disease
h """ GERD! 69Pand Dyspepsia
Insufficient 1
Da ta
3.3.2.2. Trea tm ent
"When the guide lines and the expert panel's treatment deci sions are compared the
agreement is 95% (95% CI .. 0.88 to 0 .99) as shown in Table 3.7.
It should be remembered that the expert pane l and the research team were not
independent of each other. As previousl y mentioned the research team consi sted of a
researcher who was trained by the gastroenterologist on the expert panel and a clinical
epidemiologist. The data suggests that explicit criteria and guidelines may beapplied
without an expert panel and that a research team co uld apply the guidelines provided
expert support from a physician is provided . FaTthe data demonstrated in table 3.1 a
quadrat ic weighted kappa statistic was used . The data is grouped in such a way tha t a
direct comparison is mad e between the pr-escription ofH~ receptor antagonists and proton
pump inhibitors. with all other agen ts and combinations grouped under the term 'other ' .
This is due to the similar actions of the H2RA 's and PPJ' s and the indicati ons for thei r
utilization. Whether a research nurse could apply the guidelines witho ut ex pert support to
determine the appropriate treatment is shown in table 3.9.
Table 3.1 : Comparison of T re atlDftl t DedJlons Made by tbe EI pert r a nel a nd
the Rn earch Te am
Research Team
HlRA PPI PPI+ Prok. l SM! None
Ab Combo a TC
H2RA 54 2 1
PPI 1 II
PPI+Ab 11
Expen
Panel Prok . 1
Combo
LSM! 2
OTC
None 1
42
Table 3.8 : Comp...lJoa of Trutmnt Deds60ns Made By die Rnnn:h Team aad
the Ellpert Puel usmc a WeiPted Ka.ppa Stadsde
Research Team
HlRA PPI 00."
H2RA 54 2 I
Expert PPI I
"Panel
00."
"
The weighted kappa for the abov e data continues to demonstrate a high level of
agreement between the research team and expert panel with respect to their decisions of
treatment <K,.0: 0.93; 95% CI ""- 0.72 , 1.14)
Table 3.9 : Comparisoa ofTmtmeat Decisloa, Made By the Research Nune aad
the Ellpert ranel
Research Nurse:
H2RA PPI PPI+ Prok . LSM! None
Ab Com bo OTC
H2RA 40 7 I 2 7
PPI 4 8
PPI+Ab I 10
Expert
Panel Prok . I
Combo
LSM! I I
OTC
None I
When the treatmen t decisions of the expen panel and the research nurse are compared
there is 73% agreem ent. When a weighted kappa statistic was perfonned on this data (K.,
"
= 0.50; 95%CI - 0 .30 10 0 .70). using the same method as described for table 3.8 , the
level o f agreement between the research nurse and expert panel was shown 10 be much
lower than the level of agreement shown between the research teem and the expert panel.
11was co ncluded that a research team with content expertise support could appl y the
guidelines . whereas a research nurse withoul such support could not do so . It was also
decided that in cases where disagreement occurred between the physician 's decision and
research team 's application of the guidelines, such cases should be sent to arbitration by
an independent expert panel . Cases where LSMIOTC is cited as the appropriate
treatment refer to patients whose chans record the visit in question as the first upper Gl
complaint that has been made 10 this family physician. (See figure 3.1)
3.3 .3 . 1 .~
Tab les 3. 10 and 3.11 show the percentage ofagrecmmt betw een the family
physicims" diagnosis and that ofthe expcn panel when c:ross-tabulations were performed
on the data . When GERD and nonulc:cr dyspepsia were combined in table 3.11 lire
agreement between lire expert panel and family physicians increased from 46% (9!W. C I
- 0.36 to 0.5 8 ) _ 83% (95% CI • 0.7410 0.91). A!I prniously mentioned thesetwo
disord ers req uire similar trea tment. Nonetheless 43% ofthc 14 cases that were diagnosed
as peptic ulcer d isease by the panel. were labe led dyspepsia/GERD by the family
physicians .
Table 3. 10 : CompaJilOD of DblpOSft M..sc by FamDy PIIyl ldan • • d Es pc rt Pa a e l
Ex.pcrtPancl
No nulccr pepti c GERO GERD I 0tJ...-
~. U1= Dyspepsia
Di~
Nonulccr IJ 4
Dyspepsia
Peptic Ulcer 3 • I
txseese
Family GERO IS 2 18 2 I
Physician
GERD! 9 4 I
DysDCDSia
""""
3
Diagno ses made by either the expert pane l or researc h team were based on the same
infonn ation that was avai lable to the family phys icians . The cases where the family
physician s and the expert panel differ in theic diagoosis ofPUD, are cases where there
was a positive result from an investi gation recorded in the patient's c:hlU't. Thi s
misdiagnosis would be a key factor in the Imderutilization of H. pylori eradication
thera py.
T. ble 3.11 : Com puisoa of DiapOHI Mad e by hmily Pb ysiclaa and Es:pe rt Pane l
Wb ea GERD aad NODuleer Dywpepsill an Considered Overlap
Disorden
Expert Panel
Peptic Ulcer GERO! 00",
Disease Dyspepsia
peptic: Ulcer 8 4
Disease
Famil y GERO! 6 62 1
Physician Dyspepsia
00", 3
3.3.3.2. Treatment
According to the literature and the case-based criteria thai were used , the tre atment for
peptic ulcer disease is unambiguous. This differs from the treatment for gastroesophageal
reflux disease and nonu lcer dyspepsia, whic h is dependent on the stage of the disease (i.e .
mild, moderat e or severe ).
The appropriate treatment determined by the expert panel and family physicians are
compared in Table 3.12 and demonstrate 73% agreement (95 % C I = 0.62 to 0.82) . Th is
comparison is described by individual physician in !able 3.14 and these:data are
summ arized in tab le 3.15 . The agreement hc:tween the expert panel and individual
physicians ranged from 60 - 89% . The data from table 3.12 was gro uped in such a way to
demon strate the level of agreement of the expert panel and family phys icians therapeutic
decisions using a weighted kappa statistic CK. =O.SO;95% CI - 0.29 to 0.71). The data
is grouped such that a direct comparison is made between the prescription ofH : receptor
antagonists and proton pump inhib itors. with all other agents and amtbinations grouped
under the tenn 'other' , due to the similar actions of the H2RA 's and PPl ' s and the
indications for their utilit.ation.
Tabl~ l . U : Co mparisoll of TrnbDeDt Prncribed by Famil y PIIYl ida. a.d EJ:~rt
Pa. el
EApertPand
HlRA PPI PPI+Ab Pro • . No ne LSMt
Combo OTe
H2RA 46 I 3
PPI 4 8 I
PPI+Ab 2 S
Family
Physici an Prok. 3 2 2 I
Combo
None 2 I I 2
Tab l!!' l .13 : Comparlsoa of Yrnbnnt Prescribed by Famil y Plt" ida...d EJ:~rt
Pud D. laa a Wriglt tect Kap,. Statistic
Expcr1 PaneI
HlRA PPI PPI+Ab
HlRA 46 I 3
Family PPI 4 8 I
Physician
PPI+Ab 2 S
T.ble 3 .14 : Trntmnlt Prnerlbed by EJ:pen Puel_d 6 F.-:dly P1tysicbl . ..
Expert Pane l
H2RA PPI PPI+ A b
-
No ne
Combo
H2RA • 2
Family PPI I I
Phys ician I PPI+ Ab
_ Combo I
None I
H2RA 10
Family PPI
Physici an 2 PPI+Ab
_Combo 3 I
None
H2RA 4 1
Family PPI 2 2
Physician 3 PPI+ Ab I 3
Prok Combo I 1
None I
H2RA 7 I
Family PPI I 2 1
Physician 4 PPI+Ab I
_Combo
None 2
H2RA 10
Family PPI 2
Phys ici an S PPI+Ab I
_Combo
None 2·
H2RA •
Famil y PPI 2 I
Physici an 6 PPI+Ab I
Prok Combo I
None
• Panel deci ded that no prescription treatment was needed but LSMIOTC was need ed .
T.ble 3.15 : Approprbl~ Pnscrlpdoa Ralel aad Dbposes or Eac" Oodor
Dodo' Padnl.. wtdI Pa1lft1lwtdl Appropm lc
PVD GEIlI>IDY'-'"
........._.
I • 11 1G' IS(67%)
2
"
9/14(64%)
3 6 I. 11/ 16 (tW-/.)
• 1 I' 9115 (60"/.)s - I '3 13/ 1S (8 7%)
6 2 7 819 (89%)
• the missing case c:outaincd insu fficient d.ta for diqnosj5
3.3.4. Dru. Trutme a t by Diap_
The demographic and clinical data for patients with each diasnosis as made by the
panel are shown in table 3.14. Sixty-fourpm:cnt eN"" 9) ofpatients diagnosed with
peptic ulcer disease were prescribed a treatment other than eradication therapy . Thirty sill.
percen t (N=S) were prescribed maintenance therapy with Hz recepto r antagonists.
Table 3.16 : Demognph k Data ud Dru p Prescribed by Fuilly PIIys iciaal For
Each Upper Gl DisonIer
DiagDoscs By Expert Pane l
peptic Ulcer GEROI None
0;sease Dyspepsia
N "" 14 N -" N -2
Mean Age 3' 56 3.
N % N % N %
Male • 57 43 .3 I 50
Hz Receptor 5 35 .1 44 .5 1 50
Ant agoni st
Proton Pump 1 7.1 12 18
Inhibiter
PPJ + 5 35.1 2 3
Ant ibiotics
Prokm eric 2 14 .3 • 9Combo
No ne 1 7.1 4 • 1 50
3.3.5. Utilization of Dru ., Err~ ill die Treatment of Uppe r GI Dbordl'n
As mentioned previously the measurement ofovenatilization and undenrtiliza tion is
based on whether a drug wu prescribed when DOt needed or not prescribed when needed
respectively . Tab le 3.1S shows the overuti lizatio n and undcrutil ization rates for each
upper GI drug group and these rates are shown for each physician in table 3.16.
Table3. l7 : T he OverutilizatioD u d V.derutilizatkHI Rates for Each Drue G ro u p
Proloa Pump 8 2 Receplor Andbiotks Pre kiDetics
I.hlb iton AatalOub
Pa tients W ho Needed 23 ' 7 II I
D~.
Pa tients Who Old Not 6 1 27 73 OJ
Nttd Drug
Drug Not Prescribed s , 6 0
But Needed
Drug Pres ulbed 7 6 2 7
But Not Nttded
Unde ru ti lizatio. ,/23 8/S7 6111 011
Rat e (3S% ) (14%) (S S%) (0% )
Overutilization 7/61 6127 2173 7/83
Ra te (120/,) (220/,) (3 %) (8%)
Table 3.t 8 : Ove ru tilizatioa aad Vnd erudUzation Illites of Protoa Pump Inh ib itoR
for Each Ph yl lda.
Physician PPI PPI V. de rutUkatioa OwrutiliZlltioa
....... presc ribed Rate o' PP• Rateo' PP.
I s 2 4/S(8 0'.4) 1/10(1 00/, )
2 1 0 111(100%) 0113 (0".4)
3 7 9 2J7 (29'.4) 319(33%)
4 4 s 1/4 (2S%) 2111 (18% )
, 3 3 013(0%) 0112 (0".4)
6 3 3 013(0"/,) 0/6 (O"/.)
The average number of patients seen by each ph ysi cian who needed . proton pump
inhibitor was N .. 4 and the Wlderutilization rates for each physician varied considerably.
Unfortunate ly these results, which are based a small sample population, may be
somewhat unstable and need to be verified thro ugh a larger scale study such as the one
described in Appendix E.
Tabl e 3.17 demonstrates the cases when: it was determined by the expert panel that
certai n upper Gl drugs were underutilized by the family physician and the diagnoses that
were assigned to each case by this pane l. All 6 cases where it was determined that
antibiotics were underutilized had a positive investigation (i.e . endoscopy) recorded in
their chart confirming thepresence ofpeptic ulcer disease.
Table 3.19 : Data oa ' atie all Who Sbotl1d Beve ReceiYed Dnp ror Up per G I
DllOrden Ba t Did Not Recein Them.
Pro ton Pum p H2 Receptor Antibiotics
Inhibitors Antagonists
N=8 N ~8 N =6
N % N % N %
Peptic Ulcer 6 7S 6 100
Disease
Non ulcer 2 2S 1 12
Dys pep sia
Gastro eso phageal 7 88
Reflux Disease
sa
Instances where the prescrip tion of an upper Gl drug was deemed inappropriate an:
shown in lable 3. 18. It was determined by the expen panel that S of the 7 prescrip tions
for PPIs were inappropriately prescribed for nonulcer dyspeps ia.
Table 3.20: Data for l.Bappropl'iaile PrnaipdoB'
Proto n Pump H2 Receptor Antibioti cs Prolrinetics
Inhibitors Antllgonists
N=7 N=6 N -2 N =7
N % N % N % N %
Peptic Ulcer • 67 2 2.
Disease
Gastroesophageal 2 2. 2 33 3 .3
Reflux Disease
Nonulcer 5 71 2 100 , I '
Dyspepsi a
GEROI 1 ,.
Dyspepsia
"
3.4 CONCLUSIONS
The pilot study pertaining to the prescripti on of upper gastrointestinal drugs
demonstrated that it is possible to dev elop explicit criterion-based guidelines for the
treatment of upper gastrointestinal disorders. These guidelines enable a research team to
determ ine the appropriate diagno sis and therapy for individual patients. It was also
deemed possible to collect sufficient patient specific informa tion from family phy sic ians
so that the diagnosis and therapeutic decisions of these phys icians can be compared to the
exp licit criterion-based guidelines that have been developed.
With content experti se support it is feasihle for a research team to apply the criterion-
based gu idelines to assess thenpeutie decisions made by the famil y physicians. This
statement is substantiated by the resul ts oflhis pilot study where the level of agreement
between the research team and expert panel was 1(l()O/e for diagnosis and 95% for
treatment decisions. Although there was a high level of agreement. it was concl uded that
an object ive expert panel would be helpfuJ in arbitrating between the physician s '
decisions and the research team 's conclus ions . Originally disagreement occurred in
differentia ting between gastroesophageal reflux disease and nonulcer dyspepsia. however
this was over come by co mbining the two diagnoses for mild to moderate cases. where the
treatment is similar.
It was also deemed feasible to report the overutilizatio n and undennilization rates for
the prescription of various classes of drugs through the use o( pa tient based retrospective
drug utiliza tion review and aiterion-based guidelines.
CIIAPTERIV
Antibiotic UtiUutiOD
4.1 ANTIBiOTICS : LITERATURE REVIEW
Antibio tics are arguably one ofthe mos t important advances in the history of
medicine. Sir Alexander Fleming 's discovery of a penicilhn-preducing mold in 192801
opened the door to the development of antibiotics that have greatl y reduced the morbidity
and mortal ity thaI is associated with infections. Unfortunately these ' wonder drugs ' have
been overu ti lized and as a result adverse consequences have occurred," 11 Aside from
antibiotics being expensive and/or po tentiall y toxic, their misuse appears 10 be endemic
which has greatly contrib uted to the emergence of antibiotic resistance.61 The
modificatio n o f pathogenic bacteria to form resistant strains , is now a significant factor in
the resu rgence of previously conquered life threatening bacterial diseas es.
Pathog ens such as Neisseria gonorr"oeae. Neisseria menm gitis, and Streptococcus
pneumoniae were once susceptible to most antibioti cs but have DOW fonned a res istance
10 some forms of thcrapy.u ", 6!l and subsequently spread rapidly througho ut various
counrries."" This is largely a result a f the widespread misuse and overuse of antibiotics in
additio n 10 other contributing factors . Generally theseresistanl bacteria have undergone
mutations. genetic alterations , enabling them to gain the upper hand in this rapid spread
of antibiotic resistance. For example. infections with Streptococcusp neumoniae are
among the leading causes of Hlness and death among young chi ldren, persons wi th
debilita ting medical conditions, and the elderly worldwide ."
Patients who an: no ccom plianc with the prescription rqime ft also con b"ibutonl to
the ov cnll pI'Oblcm of antibiotic raiSWK:e. Patients who cease I&king the antibiotic
when their symptoms have lcumcd arc killing the highl y susceptible bacteria but fadi n.
to dcsaoy all the pathogCflS. Powerful surviving strains ranaio which will rqxoduce and
aid in the devdopment ofrcsistant bacterial scnins." A scud)' ofparicrns . who visited .
university cl ini c. demonstrated anochcr form o f antib iotic misuse. It was apparenl chal
sclf· crcatmenl by patien ts was also a common occurreoce." including unused antibiotics
that are regularl y stored io medicine cabinets that are used freely and an: also passedon
to peop le who are suffering &omsimil ar sym ptoms ." Theseforms of an ttb iotic misuse
arc not only co ntrib uting to antibiotic resi stan ce , they can also bring harm to the patient
(e.g., unknown drug allergies).
Curren tly, over 95% o f Stapltylococcus aureJU strains are resistanl to PcniciUin G ,
with an increasing nwn bcr of strains developing resistaocc 10other anti biotics such as
meth icilli n (MRS A), oJW:illin, nafcillin, and c:epb.alosporins." Dueto the larg e nwnber
o f infections tha t an: treated within a hospical. the highly resiSWll Naerial strai ns lend 10
be found there . As. rc:sull, • significant num ber of deaths each year are due to
nosoco mial bacterial infections ."
Of recall oonocm is 1hc crt'lCI"JCnCeofruistanee to chcantimicrobial vancomycin,
VRE (vancom ycin resis1&ntcnteroeoe:ci), which bas been thoughl ofas the orny effective
trea tment for enteroeoecal infections .' · n The 1ftmcrJ:cm:e ofseriousinfections that wen:
thought to be virtual ly elimi nated (i.e., tubcn:u!osis), in tensify the neces si ty for new
antibiotics. Yet, the dev elopmenl ofnewcr anttb ioti cs has been delayed due to the
changing economic environment of hcal th care .
Not onJy has the microorganism-hwnan symbiotic relationship been affected by this
inappropriate: utilization of antibiotics, but at the:more pragmatic level it is very costly
and diverts resources that could be:channeled into other patient services. These is an
increas ing need for explicit guidelines pc:rtaining to the:treatmCflt of infection related
illness es, if such guidc:linc:swill rc:suJt in a rational approach to antibiotic therapy .
Ultim ately , th ese: recommendations for optimal c:mpiric treatment should improve: overa ll
antibio tic utilization within the community.ll
Many phannacc:utical companic:s are now searching for newer and better
antimicrobials . Yet, il will be along time before lhc:sc: recently inspired pharmaceutical
comp anies wi ll be in a position to release lhcsc: much nc:cded medications.H n Perhaps
me most useful recent advance has come: in the fonn of beta -lactam asc: inhibit ors .
"
4.2 INTERVENTIONS TO REDUCE ANTIBIOTIC UI1LIZATlON
The utilization of clinical practice guidelines has shown an improvement in
physicians ' therapeutic decisions concerning bacterial and vinUinfections.
De Santis et al. (1994 )'" performed a randomized controlled parallel group trial where
physicians frommatched, geographically separated locations were allocated to control
and intervention groups. De Santis measured the quality and appropriateness of antibiotic
prescribing according to physicians' compliance with the recommendations in the
antibi otic guidelines that they used as their n:commended tteatmenl According to the
first phase of the De Santis et aI. study , broad spectJUm antibiotics, which are discouraged
by the guidelines. accounted for 40% of the 796 prescriptions written by all participating
physicians. It was shown that after a three month educational intervention, involving
mailed brochures and a face-to-face visit by a pharmacist, the studygroup's adherence to
the reco mm ended treatment increasedfrom 60.5% to 87 .7% (P <0.05).
A study conducted by Avom et aI. (1983) 1. aimed to reduce excessive utilization of
various drugs. 435 physicians panicipated in the study and wrote an avenge of 1259
cephalexin prescriptions over a nine month period in 1980 . A significant reduction in the
inappropriate prescription of <:ephaletin per physician (intervention=1029 and
contro l- 1240) followed a face-to-face intervention.
Tw o groups of oral antibiotics were assessed in the study conducted by Schaffuer et al.
( 1983 ).IS 'Ibe first group consisted of three contraindicated antibiotics. chloramphenicol,
c1indamycin and tetracycline. with the latter pertaining to children
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under 8 years of age . The second.group included an examination o f the prescribing o f
cephal ospo rins. The intenl of the interVen tion perfunned in this study was to el imina te
the inappro priate util ization of the first group ofantib iotics aDdto redu ce, not eliminate,
the overal l prescription of the second group. During the year prior to the intervention, a
gro up of physicians (N =372) wro te 1,88 3 prescriptions for 1,08 7 patients for
contrai ndicated antibioti cs and 35,316 prescriptions for 17,636 patients for oral
cep halos porins . A red uctio n was noted in the proportion of physi cians prescribing the
contraindicated an tibi o tics (Attributable Red uctio n-18%; P=O.04 ), whereas the oral
cep halospori n prescribers continued to use these antibiotics after-the interv ention .
Sc haffner tested three forms of intervention (I ) mai led brochures. (2) vis it by a drug
educator, and (3) vi sit by a physician counselor. AJthough the dnIg educa tor and
physici an co unse lor dem onstrated an attributable reduction, it was th e physician
counselor fonn that proved 10 be most effective.
Gutierrez et aI. ( 1994)17 perfonned an educational intervention study aimed al
improving treatment of acute dianb ea by fami ly phy sicians in 2 primary health care units
in Mexico City . Throughout the intervention it was recommended that dru g prescription
be decreased and thai the usc of oral rehydration therapy be increased. An tibi otics were
one of the most common prescriptions (6 7.7%), with ampicillin the foremost prescribed
anti biotic (19 .90/0). Foll owing the intervention, which invol ved a worlcshop and a peer
review, the study group demonstrated a significant change, with the frequency of
anti biotic prescri ptio ns de<nascd from 35.4% 10 14.3% (P<O.OI). In addition to the
observed decrease in prescription frequency there was a comparable increase in the
"
prescription of the recommended oral rehydration therapy for children « 5 yean of age.
31.4% to 13.8% (P<O.OI).
4.3 SUMMARY
Research suggests that it is feasible to use criteria or guidelines in the assessment o f
physicians ' performance. Thecriteria must bescientifical ly and clinicall y establi shed
and the re liab ility and validity of using these guidelines in a certain setting must be
confirmed. The choice of intervention strategy that win be implemented to improve the
antibiot ic prescnbing patterns of physicians. depends on the results of the baseli ne
assessment. This will enable the research team to establ ish andunderstand the prom inent
areas of inapp ropriate prescrib ing behavior. The intervention should focuson these areas
and aim to enhan ce the physicians ' knowledge and therapeu tic deci sions. ACCOTding to
Hepler er at. ( 1982)u threecriteria should be met when implem enting a drug prescribing
intervention : I . theoretical validity, 2. evidence of general efficacy, and 3. evidence of
need. An ed ucational, process-orientated intervention that is aimed at the areas in which
prescrib ing beha vior is inappropriate should be encouraged.
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CHAPTER V
Utllizatioa Review of Antibiotic PracriptioD in the CommuDity:
A PIlot Srudy
5.1 RATIONALE
Newfoundland has the highest rate ofaotJ.motic prescription in Canada. Thi s is a
public health concern due ro the potential for (I) deve lopment of resistant organisms,7l 16
(2) unnecessary side effects " , and (3 ) increased health care costs." " However, even with
these life threatening concerns, the nue of bacterial infection in the population. the rate o f
inappropriate prescriptions of antibioti cs, and the reasons for inappropriate utilization are
unknown. It is this information that is needed to design an interven tion aimed al
enh anci ng the appropriate prescription of antibiotics.
Phys ician choices ofdnIgs may be less than ideal and it hasbccttshown that antibioti c
prescri bing panerns are influenced by a variety o f faet:ors such as the physicians'
approach to health care , differing standards for diagnoses. and varian t perceived patient
demand." 10 A recent study thai was perfonned in the SL John' s area, assessed a group of
family physicians' prescription pancm for ciprofl oxacin. It was determined, by both an
acad em ic and indwtry pane l separately, that between 40-1. and 60"/. of ciprofloxacin
prescri ptio ns were inappropriate. The reasons for these inappropriate prescriptions
included cheaper alternatives available . inadequate coverage of likely path ogens and
wrong indications." These results, and the emergence ofdrug-resistant bacterial strains,
indicate there is need for professional and public educational interventions aimed at
impro ving antib iotic utilization.
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The effects and patterns of antibiotic utilization are very differatt in hospitals than in
office-based practice . Broad- 10 medium-specttum: oral antibiotics, e.g ., tetracycl ines .
penicillins. and erythromycin are more commonly~bed in office practice for
respiratory infections.61 Unfortuna tely, the incidence ofantib iotic resistance is mu ch
more highly correl ated with the utilization ofbroad-spec:ttwn antibioti cs than narrow -
spectrum ant ibiotics. It bas been determined thai office-based physicians habituall y
prescribe antibiotics for viral upper respiratory infections. Seasonal respi rarory illnesses
such as co lds. upper resp iratory tract infections (URIs) , and bronchitis possess a viral
etiology in >9()01oof cases. Therefore, treatmenl with antibiotics has minimal clinical
benefit." 1l
When a patient presen ts with an Infectlon-related illness, the phy sician is faced with
two decisio ns : ( I) Whether-or not the patient needs an antibiotic prescription for their
particular illn ess, and (2) ifan antibi otic is deemed necessary, the appropriate type of
antibiot ic m ust be prescribed. The focus of the next chapter is to determ ine whether or
not it is feasi ble to assess these two deci sions made by a famil y phy sician throu gh the use
of explicit case-based criteria.
Kunin et al . ( 1913 )61wro te an exposition on how antibiotics were being USCId. They
referred to an unpubl ished stud y in which the usc of an tibiotics was judged accordin g to
the assesso rs' clinical kno wledge and relevant literature . Three of lbe five categories they
used 10 judge the use of antibi otics were applicable to the judgments made in our
antibiotic pil ot stud y. They include:
"
I. Agree with the use ofantimicrobial therapy, theprogmn is appropriate.
2. Agree with the use ofantimicrobial therapy, but a differenl (usually less expensive! or
less toxic) antimiaobial is prefemd.
3. Disagree with the usc ofantimicrobial therapy , administraIion is unjustified.
The actual measurement of appropriateness is nol faultless . The lack o f an
acknowledged standard for measuring appropriateness results in an inability to accuratel y
determine the sensitivity and specificity ofa roeasumnent tool.fl In this pilot antibiotic
study, the appropriate utilization rates are calculated by adding those patients who needed
and received an appropriate antibiotic 10 those who didn't need and weren't given an
antibiotic , and dividing by the total number ofcases.
The criteria for diagnosis and treatment of infection-related diseases were based upon
the Ontario Anti. inf ectiw Guidelines for Commllnity-ocquired Infections ." These
guidelines were developed by an independent panel , consisting offamily physicians.
specialists and pharmacists, to make it easier for physicians 10understand the prec ise role
of the man y new emi-infecrives that are used in the tmllmenl of jnfecticn-related
diseases. Existing guidelines, both Canadian and international, were the basi s ofthe
initial draft of guidelines. These preliminary guidelines were reviewed at four consensus
conferences and feedback from 120 physicians and medical associations across Canada as
reviewed 81a fifth consensus confermce. It is evident that the development of credible
guidelines is a perpetua.Iprocess, thus the second edition of these guidelines was used in
this study.
5.2 METHOD
This pilot study is a patient based. retrospective drug utilization review . Using data
that was abstracted from charts and physician interViews, an expert panel reviewed each
case to determine the optimal diagnostic and treatment decisions for infection related
illnesses. Similarl y, the research team independently applied explicit criteria for
diagnosis (Appendix K} and the Ontario Anti.injective GIIidelin~ for treatment to assess
each patient case.
5.2.1. Subject Sekdioa
This pilot study involved family physicians that were informed that • research nurse
would evaluate all the charts from their patients seen for the previous 2.5 days. A
researc h nurse recorded the total number of patients seen by each physician throughout
those days and selected only those patients seen for infection related ailment to be used in
the srudy .
Inclusion Cri teria
Physician s:
office or community based family physicians within the St . John 's! Mt. Pearl region
must consent to panicipate in the research study
Patients :
• both adults and children that prac:nted with an infection related i1Jness
"
Excl usion Criteria
Patien ts:
presenting with conjunctivitis, acne or intertrigo sincethese diagnoses were not
included in guidelines
5.2.2. Datil CoUection
Diagnosti c and treatment data, i.e., exact diagno sis, investigation and treatment plan.
were extracted from those patients ' cham, using a standardized instnunent (Append ix G).
Once the relevant data had been collected. the research nurse using a standardized
questionnaire (Appendix H) interviewed each physician. All enrolled patients were sent
leiters (Appendi x I) asking penniss ion to interview them by phone abo ut their illness.
Phone interviews were conducted to ascertainsymptom information usin g another
standard questionna ire (Appendix J). To dc:tcmtine whether the patient interview s
provided any additional infonn ation, each patient ' s symptoms recorded through these
interviews were compared to the sym ptoms recorded from the patien t's chart and
physician intervi ew . A panel assessed the diagnosis , necessity for antib iotics, and
prescription approp riateness using the criteria developed for the Ontari o Anti -injec tive
Guide/ines . The research team answered the same questions using the same Ontario
guidelines.
From the infono atio n obtained through the patients ' charts and physician interviews,
several rates were constru cted : (a) nwnber of patien ts with infection symptoms! total
nwnber of patients - a measure o f the overall burden of infection in OP practice at that
time; (b) number of infection s requiring antibiotic prescriptions! number of patien ts seen
•• a measure ofr ate ofdiagnosis ofbaetcrial infection ; (c) nwnbc:r of patients in which
..
antibiotic prescription was appropriate! nlDl1berofpatients with infection symptoms - a
"target" for level o f overall prescription and measure of competen cy of diagnos is of
bacterial infection; (d) number of appropriate selections of antibiotic (as per Ontario Anr;·
infective Guidelines)/ number o f patients in which antibiotic prescription was needed (as
determined by the panel) - a measure of competency of antib iotic selection .
The diagnosis and treatment decis ions of the fami ly physicians were compared to the
decisions made by the expert pane l. The appropriateness of the treatment prescribed by
each family physician was determined by whether antibiotics were needed, in additi on to
the frequency with which patients who neededan antibioti c were prescribed the correc t
type of agent. Subsequently a research team, independent ofthe expert panel. applied the
guideli nes for diagnosis and treatment ofinfcction·related illnesses thai were based upon
the Ontario Anli-inf«rive Guidelines to each patient case . The decisions made by this
research team were compared to those made by the expert panel.
5.2 .3, Ethics
The Human Investigations Comm ittee of Memorial University of Newfoundland
approved this study . Physicians were the focus of the study. and a research nurse and
principal investigators made initial con tact. lnfonnation was only obtained from those
physicians who signed a consent fonn (Appendix F) and agreed to participate in the
study. Although patients were nee the primary focus of this study their consent was
requ ired in order to obtain infonnation fromthem through a phone interview . Initial
contact concerning this phone intervi ew was made by their family physician and phone
interviews were obtainc:d from onl y chose patients who agreed to participate in the study.
Information was recorded from the patients who participated and the reasons for
nonparticipation were also recorded. Al l patient information was kept confidential, with
numerical identifiers for both the patients and physicians that were known onl y to the
researchers.
~.2.4 Espe:rt Puel Review
An expert panel that consisted of an infectious disease specialist, pharm~st,
epidemiologist, and a famil y phys ician reviewed the data collected from patient charts
and physicians interviews on the 98 patient cases that were obtained from the four
community- based family physicians. VsinS the Ontari o guidelines and their clini cal
know ledge they determined whether an antibiotic prescription was needed . Furthermore .
if the fami ly phys ician prescribed an antibiotic, the panel determined if the opti mal type
of antib iotic was prescn"bcd . The reasons for prescription of inappropriate antibiotic
includ e:
l. Lower line recommended (Cheaper alternative or first line agent available) - the first,
second and third line agents that are recommended in the Ontari o gu idelines were
carefully chosen according to various factors , i.e., the antib ioti c 's spectrum of
activi ty, predicted efficacy, sensitivi ty, and safety . The co st of the antibiotic s is of
impo rtan ce, especially when there are agents that have simi lar efficacy, spectrum of
activity, and safety.
2. Inadequate coverage - the U1tiJUicrobial asent prescribed does not hav e an adequate
spectrum of activity to treat the infection.
..
5.1.5. ApplkatioD of GllideliDel by the Rnurda Team
The research team reviewed clinical data on the 98 patients. obtained from patient
charts and physician inteMcws. and applied explicit ease-basedcriteria to determine the
appropriateness OftmllmenL The criteria used to make the diagnosis are shown in
Appendix K. The criteria for treatment followed the Ontario Anli-infecliw Guidelines f or
Community-acquired Injeclioru (/997).2$ The research teem was independent of the
expert panel .
5.2.6. Statistical ADaIyIls
The data for this study were analyzedwith a Statistical Package for Social Sciences
(SPSS). Various cross tabulations were perfonned to compare the decisio ns made by the
family physician or academic panel and the decisions made using the explicit criterion-
based guide lines .
Kappa scores were calculated to compare agreement between raters on decisio ns made
using the guidel ines. by the expert pane l and family physicians. This statistic corrects for
chance and allows for nominal scale assessment of the level of agreement between the
two evaluators or an evaluator and the family physicians. S'
The proportion o f agreement between the two evaluating panels was stud ied to
determine (I ) whether the expert panel review would be necessary in the larger scale
study. (2) the feasibility of obtaining sufficient infonnation through the data collection
process. and (3) the ability ofa research team to apply guide lines to make sound
judgments pertaining to drog utilization .
5.3 RESULTS
The results portio n of this chapter. I . describes the overal l characteristics of the
physicians and the patients who were invo lved in thestudy; 2. illustrates the resu lts
obtained when criterion-based guidelines are used to assess theprescribing panems of
antib iotics by family physicians.
5.3 .1. Pbysiciaa u d r atiea . C"rac:terilda
Eight family physicians were approached to participat e in this pilot study and four
agreed . Three of the four participating pbysicians represented group practice settings.
with physician #1 and #3 locat ed in thesame practice and physician #4 in a private
practi ce. All four participants completed an Interview whereeecb patient case included
in the study was reviewed.
Table S.I : Pbys ldaa C h aramriJtks
Qend" y"" #Oays # Patients
Gnduat<d Reviewed Seen
Physician I Mole 1968 2.5 II I
Physician 2 Mole 1970 2.5 137
Phys ician 3 Mole 1970 L5 83
Physician 4 Mole 1982 2.5 83
Ten of the original 108 cases with infection had conjunctivitis. acne or intertrigo and
were excluded from the study (N '" 98). Sufficient data for analysis was provided in the
rem aining cases. The patient characteristics are summarized in the followi ng table .
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Table 5.2 : PatHat Clllarade'rildcs
P.ueat CIlanC'teriJda
(N - 98)
Ag.
Mean
Rang e :s;2 yr.
3 - 14yr.
15 -24 yr.
25 - 44 yr.
45 - 64 yr.
~ 65 yr.
50s
Female
Mal.
AU.......
Sulfa
Penicillin
Pen! KetlcxlCipro
Erythrom ycin
Cep halo spo rins
System Affected
Respiratory
Geni tourinary
Skin
00"
28.8yn
4 (4.1%)
28 (28.6%)
17 (l7 .3%)
25 (25.5%)
18 (l8 .4%)
6 (6.1%)
45 (45.9%)
53 (54.I%)
5 (5.1%)
2 (2 .lW,)
I{I %)
I{I %)
l{l%)
82 (83.7%)
7(7.1%)
8( 82 '1,)
I ( 1.0%)
This followi ng portion of the resu lt section bas five components. The lint descri bes the
information that was obtained from the family physicians' assessment of the patient
during the visi t in questi on. The second presents the information that was obtained
through the patient interviews. The third assesses the congruence of the decision s mad e
by the acad emic panel and by the research team . Treatment decisions made by the fami ly
physician s are compared to the decisions made by the research team who applied the
criteri on-based guidelines which is demonstrated in the founh component. These
compari sons an: used to determine both the need for an antibiotic and the approprialeness
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of anti biotic choice. Th e final component presen ts the appropria teness of antibiotic
utilization for the four participating physicians .
5.3.2. FamDy Pb ysic:iuls' ASHAme.!
Thro ughout approximately 2.5 days, the four participating physicians saw 4 14 patients
in tota l of which 26.1% were classified as having an infectio n. The mean age for these
108 patients was 28.6 years (range 6 mths - 80 years) and 54.6% (N =S9) were female .
The rate of diagnosis ofbaeterial infection (as determined by the family physicians '
prescription of antibiotics) was 1.0"10: - 29 antibiotic prescriptions for preswned bacterial
infectionl41 4 patients seen by the physicians .
A comparison is made of the rate cfmfecncn and prescription in Table S.3 for each o f
the fo ur physicians thai participated in the stud y. The average rate of infection was
26.8% (range 21%·31%) and the rate of antibiotic prescription ranged from 6% - 8%.
Table 5.3: Com paritoa of the Ratn of Infection ad Prescriptioa for each
Pbyskiaa .
Rate of Rate of Rate of
infectio n prescription prescription for
overall infection cases
00<10, I 28/111 9/1 11 9/28
25% 8% 320/0
Doctor 2 29/137 8/ 137 8/29
2 1% 6% 28%
Doct",3 2S183 SI83 S/2S
300/. 6% 20-.1000<10, . 26/83 7/83 7/26
31% 8% 27%
The percentages of various forms of infectio n related illnesses thatwere seen by the
physicians are shown in table S.4. Uwer respiratory infection accounted for 76% of all
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infection-related illness, skin and soft tissue infcaioa 12%. urinary tract: infection 6.5%,
other infections 5.5%.
Table 5.4: lUte ofDiaposilud Aatiblotia PnKribed for Ea ch Type of
I.redio.
URI UTI Skin Other
N patients with 82 7 13 6
diagnos is
% patients with 76% 6.5% 120/0 5.5%
diagnosis
N antibiotics IS 4 7 3
prescribed
% anti biotics 18% 57% 54% 50%
prescribed
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5.3.3 . '.deat Tele:pboDe IalenHws
The patient telephone interviews were conducted to determine the feasibility of
obtai ning any additional relevant information pertainiJ'Jg 10 the patient 's visit and the
propo rtion of patients who could be contacted for a telepbooc interview . We tried to
contact 108 patien ts (including patients with conjunctivitis. intertrigo , or acne). Only
63% (68/ 108) of the patients could be contacted for phone interview s. The reason s for
this low rate of participation are described in table 5.5. See Appendix J for theprotocol
used durin g the telephone interviews .
Table 5.5: ReasoDI for Noapartidpadoala Te lep .oae b ter"Yinn
ReuoIU N-.fO
Patient requested Dot to be called 10
Sensitive nature of illness 4
No phone number available 3
Patient co uldn 't recall the visit 2
Patient was in hospital I
Patie nt couldn' t be reached 20
Some data obtained from the 68 patients who participated in the telephone interview
are shown in table 5.6.
InformatioD From PatiCllt
Expected an antibiotic
Received an antibioti c
Filled the prescription
Early tennination ofantibiotic
(n onco mplian ce)
W ould be disappointed if they weren't
pr escribed an antibiotic
Would travel > 2 hrs to nearest
ph ys ic ian with thi s illness
O n a drug plan
N- 68
38 (55.gela)
19(27.9018)
18 (26.5%)
3(4.4%)
18 (26.5%)
35 (5L 5%)
43 (63.2%)-
• 5 patients were unsure if they were on a drug plan or not
Of the 38 patients who expected an antibiotic. 19 did not receive an antibi otic , of
which 10 were disappointed that they weren' t prescribed an antibiotic. Of 19 patients
who received an antibiotic I did not fill the prescription and a further 3 were not
com pliant.
Info rmation on primary symptoms obtained from the physicians and the patien ts
revea led agreement in 90"/. (6 1/68) . There were S other patient cases where more
info nnation was obtained from the physi cian 's data, which further suppo ns the
ass umption that the in fonnation obtained from the physician and patient is proporti onal in
97% of cases (66/68). Tabl e S.7 describes the cases where either the family physician or
the patient provided more information pertaining to the symptoms presen t at the time of
the visi t . In the 2 cases where infonnation differed between the inform ants, the
thera peut ic deci sion was the same .
"
Table S.7: Sip. a d S)'IIlpt.... .. Recorded by th e FamDyPhyskiaa _d r adeat fa
7 CaseaWhere Th ere Was Not Apeemeat BetwHa die 1 Souftft.
Case Number S)'IIlp tolDl Recorded By FunDy S)'IIlpt:oms Recorded By
...-
ratic.t
1 car ache , headache, redness, itching ear , dryness
itching, pain
2 ear ache, red TM , fluid discharge, irritable, pulling at ear ,
seven: pain decreased appetite
3 car ache. red TM, sore throat, poking at ear , pain, fever
febrile
4 coryu., rales, sore throat, cough stuffY head.cough
s coryza, cough, sore throat, fever , cough, chest congestion
rates, chest CODlestion
• sore throat, rales cough, ccegeseon, sorethroat
7 coryza, cough, congestion, rhonchi sore throat, fatigue,
congestion
TM = tympanic membrane
Alth ough this tables refers to disagreement, some of the data recorded from famil y
physic ians were observations and clinical terminology that the patients would not able to
recall. In view of the low patient interview rate and the high agreement between the
docto r and the patient concerning symptoms. it was concluded that patien t interview was
not necessary for a review of antibiotic utilization. Should data be required concerning
patient compliance or expectation. then patient interviews would benecessary.
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5.3.4 . Research Team n. Es pert Pod DedlIo.1
For each of the 98 patient cases included in the assessment it was determined whether
an antibiotic prescription was needed . If an antibiotic was prescribedand needed. it was
also decided whether the cho ice of antibiotic was optimal .
If the expert pane l is cons idered the gold standard, the characteristics o f the
applicatio n of the gu idelines by the research team demonstrate a sensitivity of )00'/0 and
speci ficity 96%. This is not surprising since the expert panel used the same criterion-
bas ed guidelines as the research team . The comparison of the two panels' decisio ns is
shown in table $.8. The three occasions where the panel and the researchers differed in
therapeutic decision areoutJined in table 5.9.
Table 5.8: Com parilo. of DecUIoIi. Made by tile Rneardl Tea m and
the El.pe rt Panel
Expen Pane l
Antibiotic Antibioti c Not Total
N"""" N""""
Antibiotic 2. 3 23IResearch N""""
Team Antibiotic Not 7S 75
Noeded
Total 2. 78 98
The above compariso n of the therapeutic decisions made by the two panels
dem onstrates agreement in 97% ofdecisions regarding the necessity for an antibiotic
(95% CI = 0.91 to 0.99) . The kappa score was 0.91.
Table 5.9: Patit .t Cases W here dte Pu ds Ourered ill n erapeutk Oed slo as n
NecesaityrorAadbfotk:
Padeat Ph,....... Ph,. ..... Resea rcll te alD EspertPneI
Case Dlaposis TrubDellt
I sinusiti s no prescription antibiotic needed no antibiotic
needed
2· otitis media antibiotic antibiotic needed no antibiotic
prescribed needed
3 folliculitis antibiotic antibiotic needed no antibiotic
prescribed needed
* this cas e was a recheck after a 10 day treatment with an antibiotic which caused an
all ergic reaction . Sympt oms had improved but not disappeared.
Ta ble 5.10 compares the decisions made by the research team and the expert panel
conc erning the appropriateness of the choice of antibio tic. Using the expert panel as the
go ld standard . the sensitivity of using a research team to apply the guidelines was 80"10
and spec ifici ty was 100"10. i.e., 12 bad received appropriate antibiotics according to the
research team , of the 15 patients who the expert panel felt bad received appropriate
enubtonc s (80".4),and 5 had not received appropriate antibiotics according to both the
research team and expert panel ( 100"1.).
Table 5.10: Appro priateness or Aatibiotk Prne:rtpdoDSDeemed Neees..ry
Expert Panel
Antibiotic Antibiotic Not Toul
Appropriate Appropriate
Antibiotic 12 0 12rR~OMCh Appropriate
T,~ Antibioti c Not J 5 8
Appropriate
Total 15 5 20
Agreement concerning the appropriateness of choice o f antibiotic was 85% (95 % CI -
0.62 to 0.9 7), with a kappascore of 0.67.
Table 5.1 1 describes the 4 cases where the research team and tbc ex pen panel differed
in their opinio n re the appropriaten ess ofchoice of antibiotic prescribed by the family
physician. Tab le 5.10 included only the cases where an antibiotic was deem ed necessary
by the expert panel. thus showing 3 cases where the panels differed . How ever, there was
a patient case where the research team felt an antibiotic was needed but the inappro priate
choice of antibiotic was prescribed, whereas the expert pand deemed an antibiotic
unnecessary (see table S.II).
Table 5.11: Comparisoa of Dedlloa s M He By tb e Es per1 PuellUld the
R~ Tum ill die 4 Cases Fe Appro prbteBftI of Choice of
ADd biodc
P.dent n yt iciaa Rnard.Tam Espert Paael DHls ioa
Ca..
_.
I Folliculitis Inappropriate • Not needed
inadcqua1C covc:n.ge:
, Dog Bite Inappropriate . A PPropriate
inadequate coverage
3 Otitis Media lDappropriate - lower line Ap propriate
n<o""''''''''''4 UTI Inappropriate. lower line Appropriate
reccmmeeded
We concluded that the research team was likely to apply the guidelines more
vigorously than the expert panel but that it would benecessary to describe the reasons
why antibiotic choices were considered inappropriate. This is because the qual ity ofcare
should be detennined by whether adequate coverag e was provided rather than by cost .
However there are instances where the ccst-effecnveeess of the antib iotic prescribed is a
factor, such as those cases in this pilot study where an equally effective and less
expensive antibiotic is available and recommended.
5.3.5. Assnlmeat of Trea tmeD t DedI'o .1 by. Rneudl Team ApplylBl G uldelilln
Using the guidelines applied by the ftSaIrCb. team, we assessed the decisions made by
the famil y physician re(a) the oea:ssity for anbOiotics (Table 5.12) , (b) appropriateness
o f antibiotic choice andthe reasonsthat thechoice was DOt appropriate (Table 5.13). The
decision s made by the research team. were used as the standard in lieu of the expert pane l
due to the published nature ofthe Ontario guidelines, which required that they were based
upon consensus and underwent peer review .
O f the 22 prescriptions of BnbDiotics that were made by the famil y physicians there
was 100"/0 agreement with the research team. pertaining to the necessity of antibiotics .
However , the criterion driven approach demonstrated that therewas I patient where an
antibiotic was needed but was not pmJcribed by the family physician. Thus, the
overu tilization score was zero and the uodcrutilization score was 4 .3% (Table 5.16).
Table 5.1%: Comparisoa of DedlioD' Made by die Reseatth Tea. a d
the Family Pbylidal
Family Pb)'iician
Antibiotic Antib iotic Not Total
P=bed P=aibed
Antibiotic 22 I 23I R~=h NeededTeam Anttbiotic Not 75 75
N.......
Total 22 7. 98
Altho ugh the decision to utilize antibiotics by the family physician was highly
appropri ate, the choice of antibiotic was less appropriate, as shown in table 5.13. Of22
so
decisions to prescri be an antibioti c. 41% were considered to involve inappropriate choice .
The nine differ-ences between the actual decision and the research team are ou tlined in
table 5.14.
Ta ble 5.13: A pp rop riatea ell of tile CIIoke of Aadblodc Prescribed by th e FamUy
PbY1ltc:lan s
Research Team
Antibiotic Ap ate 13
Antibiotic Inappropriate 9
<a) Inadequate Coverage S
(b) Lower-line or cheaper alternative 4
recommended
• Three ofthese 22 prescriptions were forropica1 agmts
Ta ble 5••4: Panels ' Th enpead e Decblo.s C OII«naiIla:tile Choke of Andblod c:
Prnutbed by the Famil y Pllyakbut
Patient Family Physician Type:ofAntibiotic Research Team
c= Diagnosis P=cribed
1 dog bite cloxacillin inadequate
coverage
2 UTI norfl oxaci n lower line
recommended
3 community acquired amoxicillin inadequate cov erage
pneumonia trihydrate
4 folliculitis trimetheprim- inadequate coverage
sulfamcthoxazole
5 otitis media amoxicillin- lowcr line
c1avulanate recommended
6 co mmunity acquired c1arithromyci n lower-line
pneumonia recommended
1 impetigo gcncam.icin inadequate coverage
sulfate
8 pharyngitis amoxicillin inadequate coverage
(5trep throat) tribydntte
9 UTI amoxicillin lower line
tribydratc reccmmeeded
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Although all presa1ptions ofantibiotics were analyzed. it is the oral antibiotics that
arc of greater significance. Tab le 5.15 stratifies the type of antibiotics that were
prescribed by oral and topical agents, and dcmonstnltes whether or not the guidelines
confirmed that the: antibiotic was needed and whether the appropriate antibiotic was
prescribed.
Table 5.15: Comparisoa 01Ora) aad Top ical Aadbioti a; Prescribed by the
Pbflk:laa l as DetenailHd by tile Researc.b Team
Oral Antibiotics Topical Antibiotics
# Prescribed 18 4
# Needed 18 4
# lnappropriate type of (N.7) (N -2)
antibiotic pracribed
_Alternative 4
_mdcd
_Inadequate coverage 3 2
"
5.3.6. Drua: VtillZlltioa SCorft by PIIysidaas
Table 5.16 stratifies the overuti lization. underutilization andappropriateness scores COl"
each of the family physicians.
Table 5.16: Vtilizatlon IUIId Approp rla tellnl Seons for Each Family Physician
Family (a) Ovcrutihzation (b) Underutilization (c) Appropriateness
Physician Score Score Score
1 (0118) 0"10 (l /S) 200'" (19 /24) 7CJ-'"
2 (0120) O'"A. (017) ()OJ. (26/28)93%
3 (0120) O'"A. (0/4) 0% (21124)88%
4 (01 17)0"10 (0/6) 0% (21123) 9 1·'"
The scores for the above table were determined by the followi ng frequenci es :
<a) '" Antibiotic prescribed and not needed! N where antibiotics not needed
(b ) '" Antibiotic not pracribcd but needcdIN antlbiotics needed
(c) = Antibiotic prescribed, needed and choice appropriate + anub iotic not prescribed
and not needed / N infection cases
The appropriateness score that was calculated for each physician can be swnmarized for
the total group (N = 98) by including the cases where an antibiotic was not prescribed and
no t needed (N = 75) wi th the cases where an an tibiotic was prescribed. needed and thc
choice was approprialc (N " 13). This results in an appropriateness scoreoflJOl'/o
(8 8/ 98).
"
50! CONCLUSIONS
Through the implementation oflhis pilot study regarding the prescription of
antibiotics it was deemed possible to collect sufficient patient specific data from
physic ians so that the diagnosis and therapeutic dedsions can be compared to the Ontario
Anti-inf ective Guidelines . From the results of the 68 patient telephone interviews that
were conducted it was considered to be unnecessaryto interview patients because more
cl inical information is not provided over and above that provided by the family physician.
It is feasible for the research team to apply the guidelines to make decisions on the
necessity of an antibiotic for individual paticots. anddocsnot ~uire an expert panel to
review all of the patient charts. This statemcot is supponed by the 97% agreement that
was demonstrated when the decisions of the research team andexpert panel,regarding the
necessity of an antibiotic. were cross-tabulated (K = 0.91). However, a lower percentage
of agreement was demonstrated wbee !he research leam and expert panel 's decisions
pertaining 10 the appropriateness of choice of antibiotic were compared (85%. K = 0.67).
This decrease in the rate ofagreement suggests that solely the research team should not
make decisions regarding the appropriateness of the type of antibiotic prescribed.
It was also fowxl to be possible to report the overutilization and underutilization of
antibiotics that arc pracnbed by famil y physicians.
..
CHAPTER VI
The main objective ofboth pilot stud ies was to evaluate the feas ibility ofutilizing
explici t case-based cri teria to assess the diagnosis and therapeutic deci sions made by a
family physician.
Each study addressedan area of med icine ofconccm to the Department of Health o f
the Province of Newfoundland . One concentrated on the utilization of upper
gastroi ntestinal drugs , and theother on antibiotic prescription. This section will discuss
the methodo logical considerations and the various limitations associated with each pilot
study , and then we wi ll discus s the larger studies where some possible solutions will be
ad dres sed .
6.1 LIMITATIONS OF PILOT STUDIES
6.1." Data CoUection
A medical history is completed for every patient who visits a physician. However. the
amo unt of infonn ation documented in each chan varies among physicians. Therefore.
one method ological issue concerned the feasibility of retrospective data collection to
determine the patient's individual needs . The data cctlecnce process used in both stud ies
is lengthy. Each patien t chart must be reviewed thoroughly to ensure that a comp lete
med ical history is obtained. This comprehensive patient profi le is essential for the expert
and research panels to apply the guidelines and accurate ly delemtine the optim al
therapeutic decision .
"
Although the degree ofinformation recorded by eachphysician in the patients' chart
could vary, there were few instances in which the panel was unable to make a decision
because of inadequate information. This may bave resulted from the use ofa
standard ized data abstraction form and a physician interview subsequent to chart
abstraction, whereby the interview substan tiated the information compiled from the
patients ' charts and in some cases , provided additional iafcrmance. Onl y I case was
reject ed in the upper GI study due to inadequate data and none in the antibi oti c study .
6.1.1. Applkatioa of GulddiDet by • Retalrdt TdJIl to Ann. Approprbteaesl
6.1 .2.1. Uti lization ofUpper GI Guidelines
The Newfo UDdland guidelines for the treatment ofuppcr gastro intestinal disorders,
together with a mul tidisciplinary expert pand andan extensive literature review, were
involved in the development of optimal diagnosi s and treatment guidelines (Appendix C) .
Th e decisions made by the expert panel were compand to those of a research team
applying the gu idel ines , which demonstrated a substan tial disagreement between the two
methods concerning original diagnosis, particularly for nonulcer dyspepsia and GE RD.
This resulted from (a) the vague and nonspecific nature of the symptoms (b) the sim ilari ty
of the symptom s tha t characterize both gastroesophageal reflux disease: andnonulcer
dys pep sia, and (c) differences in the way that past and CW'T'Cntsymptoms were integrated
to make a diagno sis. Frequently patients with symptoms ofGERD had symptoms of
nonulcer dyspepsia in the past, and vice versa. When the two disorders were considered
an overlap conditio n, GERDlDyspcpsia, diagnostic agreement increased to 100"/0.
A 95% agn:cment between the raean::her and the panels' therapeutic decisions
enabled an inference that decisions concerning the optimum treatment regime could
reasonabl y be based primarily on symptOmS, signs and medical history rather' than a
speci fic diagnosis. It has been shown that there is a high proportion of patients with Ill -
defined symptom s, which in tum makes it difficult to treat a patient based on an accurate
dia gnosis.' Beers et al. (1997~ demonstrated that it is feasible to evaluate the utilization
of medication with criterion-based guidelines in theabsence of specific diagnoses. It has
been necessary to use this approach with guidelines in instances where relative
inaccuracies exist in certain medical records , Le., nursing home records.
6.1.2.1. Utilization of Antibiotic Guidelines
The criteria used to assess the family physicians' then.peutic decisions were based on
the Ontario Anti -infective Guide/inufor Comnnmiry.acquired lnfections (1997)." These
guideli nes were consensus driven, evidence based and published. However, there were
instances where the expert panel 's c1inica1lmowledge caused them to veer from the
reco mm ended line oftreatmmt. Comparisons of the expert panel and decisions made by
the research team using the guidelines demonstrated strong agreement concerning
decisions on whether' a prescription for an antibiotic was necessary. This agreement
dimin ished when decisions on the appropriate choice of antibiotic were assessed.
Analys is of each case in which disagreemenc occurred between the two methods
sugges ted that adherence to the guidelines was preferable. It was concluded thac it is
feasible for a research team to determine the necessity for an antibiotic through the use of
guidelines that are applied to information obtained through extensive data procedures.,
which included patient infOmUltiOO extracted &om the chartby a nurse, physician
interviews and patient interviews.
6.1.3. Study Population
In the antib ioti c study, four of the eight pbysicians who were approached re fused to
participate in the study. The physicians who agreed to participate have well establi shed
practices and it could be assumed thatthey are confident in their prescribing beha vior .
The low rate of antibiotic prescription and the optimal therapeutic decis ions that were
made by these phys icians would support this hypothesis.
A larger and more diverse group of physicians is required to ensure that the data
collected is representative of what happens in the community. It is hoped that if 80% of
all physicians in the St . John ' s - Mt. Pearl region participate in the larger stud y both
approp riate and inappropriate prescribers will be represented in the study population .
..
6.2 PROPOSED COMMUNITY STUDIES
Two studi es were designed to assess drug utiliution in the community. The protocols
for these larger scale studies were based upon the pilol studies that were discussed in this
thesis. (See Appendix E & L)
The objectiv e of the upper gastrointestinal (VGI) study is to assess the utilization of
VOl drugs within the communi ty and to detenninethe effectiveness of an educati onal
interventi on on the tmprovement of the appropriate prescription of these drugs by family
physicians. i.e. reducing underutilization ofproton pump inhi bitor. This study will be a
randomized contro lled study involving rettospective patient chan review by a research
nUJ'5c. Subjects will berandomized 10 intervention or control groups and followed to
document o utcome. Through the usc ofaccepted criterion~basc:d guidelines, the
appropriateness ofprescription will be measured in bolh groups to ascenainif the
intervention was effective.
The seco nd study's objective is 10determine the rate ofantibioti c prescripti on in the
treatment of upper respiratory , urinary tract and skinand soft tissue infections within the
community and whether it is possible to reduce the rate ofoveruti lization of antib iotic
prescription through the tmplementa tion of an educational interventi on. This will be a
pre/post intervention trial where the prescription behavior of family physicians will be
assessed . A retrospecti ve review of patient clwts by a research nurse will provide the
information needed to determine whether the antlbioti<:prescription was necessary and
whether the appropria te antibiotic was presaibed.
"
6.2.1. Limiudons o r llle Proposed Commga lty StlIcUet ud POol StlIdJes
Certain areas within the protocols and pilot studies present limitations that need to be
address ed.
I. Method of recrui tmenL A physician's consent is required before any charts can be
review ed. This introduces the Hawthorne effect, whereb y the knowledge that their
behavio r is being monit ored in a study may alter the prescrib ing behavi or ofthe
participati ng physicians. 16 Furthermore, subjects who volunteer to parti cipate in a
study are not randomly selected and represent a distinct group whose generaiizab ility
10the total population of physicians is significantly reduced. It is this vo lunteer nature
of the study subjects which creates an inherent bias. The physicians who do not agree
10participate in the stud y may be the very phys icians who arc prescribing
inappropriately.
With the use of the provincial database (MCP) the Hawthorne effect will be mon itored
by meas uring the tate ofantibiotic prescription! number of patients seen before and
after the study. If prescri ption rates decrease during the base line study it woul d
suppo rt the Hawthorne effect . However, it would also demonstrate that prescribing
behavior can be influenced by the processofdrug utilization review .
2. Retrospective review o f medical records . Misc lassification bias may occur if pertinent
findings and information from the clinical history and examination are absent from the
patient's record or are recorded improperl y." iii For example, previous investigations
and past medical history are necessary to detlCfll1ine whether the dyspeptic symptoms
experienced by a patient are ulcer or nonuicer in natw"e. Similarly , in many cases there
is a fine line between whether an infection is bacterial or viral when relyinJl only on
the patient's symptoms and clinical history to make diagnostic and therapeutic
decisions. J1 Both cases substantiate the importance of a co nsisten t and thorough
med ical history for each patient.
3. Physi cian interview. As physicians verify and/or provide addi tional infonna tion
co ncerning their therapeutic decisions this could bias results in favor of thar decisions .
Although it is though t that the interviewers'!mowledge o fthe research hypoth esis may
cause such a bias . it is unlikely since the majority of data is obtained from the patients'
In some instances in the upper GI stud y the physician was required to recall a visit that
occurred some months prior to the interview . This increases the distinct possibili ty of
either recall error or bias occurring. U yet it is assumed tha t the infonnation obtain ed
from the patient ' s chan will alleviat e some of chis bias . Unlike the upper 0 1study, the
physician interviews for the anti-infecti ve study took place no later than threeda ys
following the visit in qu estion, limi ting the issue of recall bias .
4. Concurren t even ts which may influence the results of the stud y (cointervention) .
According 10 Guo et at. co intervention includes phannaccutical co mpanies '
promotio nal detailing, patients ' demands . noncompl iance, federal or states policies,
clinical phannacists' consultations. third-party payerreimbuncment policy. cos t of
medicati ons . or academic conferences, meetings, lectures and seminan.l1 A particular
event which occurred in the middle of data collection for the upper GI study was the
restricti on of proton pump inhib itors by the provincial drua: formulary, Physicians
were required 10 fill out and submit forms to warrant a .,.-escripti on for proton pump
inhibitors. This newly implemenled restriction may have altered the physicians'
prescribing practices.
5. Randomization. In lieu of randomizing the physiciam individually, the concept of
randoml y allocating the S\lbjects by physician practices wasconsidered. If we used an
appropriateness score per practice u the primaIy outcome measure 56 practices would
need to be enrolled. bUI this would not be feasible within the geographic area of the
proposed study (St . John 's-Mt. Pearl region). It was thought that this method would
eliminate some oftbe contamination that is attributable to the Cll:changeof infonnation
between the control and intervention subjects within the same practice.'" However, this
would nOIexclude the communication of infonnation among physicians throughout St.
John' s and Mt. Pearl, some of whom may be in the inlervention group.
It is anticipated that the presence of. control and intervention pup will reduce the
effect that cointervention will have on the results. This coimerventtcu may be a result
of information from pharmaccMical representatives, peer physicians and available
literature. If the subjects are truly randomized to the two groups , it is assumed that any
changes that are not a directresult of the intervention will be demonstrated in the
contro l group.
6. Generalizability. Clearly the pilot studies do not reflect what is happening in the
comm uni ty, u only a few select physicians participated. This will be alleviated in the
community based study because it is hoped thai the family physicians who are
randomly allocated 10 the control and intervention groups will provide two groups thaI
are simi lar in chara<:teristics. However, only those physicians who agree to participate
in the study will beenrolled in the randomization processwhich may cause the
"
generu.lizabi lity of the results to be questionable. To generalize the results to the rest
of Canada,one must assume that when com pared to Newfoundland. ph)'5icians '
educati on. health care delivery and patients are simil ar in the other provinces.
7. Seaso nali ty. It is recognized that respiratory infections have a higher incidence rate
during the winter months.90 9 192 This pilot study on anti biotic utilization rook place
during the last week of May an d first week of June , at which time the rate of infecti on
is prob ably lower. It is possible that during the winter months the physicians are
overw helmed with patients and ma y not have sufficien t tim e to completely assess the
patient. Thi s may result in a pr-esaiption of an antibiotic as an indication that the
cons ultation is over .'
8. Sample Size . Initial ly, the sample size calculation for the upper- 0 1study did not take
into aCCOWlt the problem of assuming independ ence of the indi vidual treatment
decis ions made by each ph ysi cian . To achieve this sam ple s ize each physician wi ll
enroll 18 patients into the stud y of which it would be assumed that 5 patien ts need
proton pump inhibitors. Thus. simi lar patients may be entered into the stud y and may
not be con sidered independent of each other .
To overco me thi s prob lem of independence it was decided to use an arbitraril y
appointed score for each physician. Thus . the physicians themselves are used as the
basis of the calculation (or the unit of randomization) rather than the patient vis its.
However , it is not clear how many patient visits would be necessary to provide a val id
score for each physician . Furthennore. the pilot study does not reall y provide a
reasonable estimate of the range ofscores per physician, or the likel y averag e score for
"
physicians in the co mm unity. It is shown lhat bothways of estimating the sample size
have their limitatio ns.
Although it is common practice to use a tw o-sided hypothesis, a one-si ded hypoth esis
was used in the design of this study . The primary outcome of the study was to
determ ine the po sitive effect that an intervention bad on the intervention group . This
positive outcome was shown by an increase in the physicians' adheren ce to
recomm ended guid el ines and criteria. A negative outcom e would be classifi ed as no
observ ed chang e in the prescribing patterns of the intervention group, as it is assumed
that the intervention will oot have a negative d'fea on the prc:scribing practice of the
participating physicians.
9. Blinding. Due to th e necessity for a physicians ' consent to participate in these stud ies
it is not poss ible to completely blind the sub jects. Although the participating
physicians will not be aware of what the study speci ficall y entai ls, they will know that
their patients ' charts are being reviewed and this may alter their prescribing patterns
(Hawtho me effect). Retro specti ve data co llecti on from patients' charts , rather than
self-repo rting by physicians , is used in an anempt to eliminate as much bias from the
physician as po ssible.<OO If physicians know they an:in the co ntro l group they may
acquire new inform ati on and thus confound the beneficial im pact of the educa tion al
interven tion.
6.3 STRENGTHS AND WEAKNESSES
The strength ofthese intervention studies is that they allow the physici8J1S to learn
more about their prescription patterns and will give them the oppommity to improve the
level of care that they give to their patients. Continuing medical education (CME) is an
essential aspect of clinical medicine and through this SNdy the physici8J1S who are in the
intervention group will receive CME pertaining to diagnostic and treatment guidelines for
upper GI disorders and infection-related illnesses. The pre- post design of the antibiotic
study is a result oftbe Department of Health of Newfoundland and Labrador requirement
that all physicians be given the opportunity to receive the same infonnation rather than
just a select group . If this intervention is effective in enhancing optimal prescribing
patterns, it will improve the level ofheaJth care that is provided to the patients ofthe
physicians in the community . The actual length of time that the physicians will sustain
the effect of tbe intervention and prescribe optimally is unknown. A follow up period, six
months after tbe third phase, would give a good indication of the sustainability oftbe
intervention 's effectiveness in the physicians of the study group .
The main weakness is the requirement for. physician 's consent to participate in the
study such that necessary infonn ation can be obtained . Some physicians may feel
threatened that their practice of medicine is being monitored. As previously mentioned a
change in their prescribing panern may also occur due to the knowledge that they are
being assessed. It is necessary for measures to be taken, i.e. control group or external
validation, to ensure that this bias is accounted for in the results.
CHAPTERVD
Summary aDd CODclusioDS
Drug utilization review is an appropriate means of determining the appropriateness o f
prescription by physicians within a commwUty. OUR may be paticnt.based or registry
based depending upon the infonnation required to answer the research questions . The
desi gn o f lhe OUR that is used ma y beeither rctrosp«tive: or prospective. with the former
having been proven the most feasible and cos t-effective:method for current usc . The
utili zati on of guide lines to assess physi cians ' prncribing behavior was discussed,
including the development of guidelines, their invol vcment in quality assurance, the
im plem entation of these guidelines to assess physi cians ' practice, and how these
criterion-based guidelines are used in performing a OUR .
Both guidelines and interveeaons are used to improve the appropriaten ess of
prescri ption by physicians. Th e measurement of appropriateness has been discussed and
the most effective fonn of intervention has been established as being a face-to-face
interventio n that is conducted by a peer physician. Clinical practice guidelines developed
by physicians from clinical and scientific knowledge in conj unctio n with clinical trial
da ta are more likely to be accepted by physicians in general Th is is under the
presumption that each guideline has been tested against actual patient cases prior to their
implem enta tion, which would not bepossible with registry -based OUR.
The utilization review ofdrugs effective in the treaanent of upper gastrointestinal
disord ers determined that it was possible to collect patient specific data from physicians
and it was feasible for a researcher with conte:ot expertise support to appl y the guidelines
ss
to these data. It is possible to report the over/underutiliution and appropriateness rates
from this fonn of retrospective patient-based OUR.
A large scale study is needed to assess the effectiveness of an educational intervention
in improving the appropriateness of prescription ofdrugs for upper 01 disorders and the
issues arising from the design of this study were addressed .
Antibi otics are of extreme importance but their misuse contributes to the global problem
of an tibiotic resistance. Various studies have been performed to reduce antibiotic
ovcruti liza tion through an educational intervention.
A retro spective patient-based OUR of antibiotic utilization determined that it was
poss ible to collect patient specific data from physicians and it was feasible for a res earch
team with content expertise support to app ly the guidelines to these data. It was deemed
unn ecessary to interview the patients as no additional clinical information was provided
through this process. It was detcnnined through this retrospective DUR that it is possible
to repo rt the ovcru tilization and appropriateness rates using this method of evaluation.
A larger scale study is necessary to accurately assess the extent of antibioti c misuse
within the community. The fonn ofintervention that is to be usedin this stud y will be
det erm ined subseq uent to the baseline assessment.
The util ization of various drugs has been less than ideal due 10 inefficiencies in
physicians' prescribing practices. Further rcscan:h is ncccssuy 10 determine the actua1
extent ofthcsc inefficiencies and whether an educational intervention will have a
favorab le effect on improving inappropriate presaibing practices. This thesis
investi gated the feasibility of using criteria and guidelines to assess the remedial
effectiveness of drug uti lization in the community. It was established that a researcher
could collect the necessary infonnalion and utilize predetermined mll:ria andguidelines
to determine the optimal lreabnent regime .
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AppendhA
FacuJtyofMcdicine
Memorial Universi ty ofN ewfoundJand
SL John 's, Newfoundland AlB 3V6
ConHnt To Partldpate I. Bfo-MedkaI Rnearch
Title: The Effectiveness of an Educational Intervention on The Improvement of
Physi cians ' lnappropriate Prescription o f UpperG( Drugs
IDvntigators: Or. F. Buney
IN. P.P"",""
Sponsor: Astra Pharma Inc.
You have been. asked to participate in a research study. Participati on in this study is
entirely vo lun tary . You may decide not to participate or may withdra w from the stud y at
any time.
Confidentiality of informa.tiOQcooceming participants will be maintained by the
investig ator. The investigator will beavailable during the study at all times should you
hav e any problems or questions about the study.
The Purpose ofthe Study .
Clinical practi ce guidelines have been developed to improve the diagno sis and treatment
of upper gastro intestinal disorders . The use of an intervention designed to increase the
use of clinical practice guidelines by primuy care physicians may im prove the qual ity of
patient care.
A pilot study bas beencompleted and has proven the feasibility of this intervention study .
Th is study will demonstm:e the frequencyof each diagnosi s as well as the frequenc y and
type of treatment~bed for eachconditi on . The study will determine the
effectiveness o f an educati onal interventio n on the improvement of phy sicians '
inappro priate prescription o f upper 0 1drugs .
Description of Proc:edures and Tests
You will be asked to review a list of your patients who have been seen recently for upper
0 1disorders. These patients will be iden tified through the use of your <:Ompurerized
bill ing codes . These codes will identify patients with gastroesophaSeal reflux disease ,
esophagitis, peptic ulcer disease, gastritis , and tlmctional disorders including nonulcer
dyspepsia.
A research nurse will interview you using a uniform abstraction instrument. Data on aU
patients will be obtained from the charts and from the interview.
Duration of Subject Participation
You will be asked to des ignate a period of time from your practice to review all cases of
upper GI disorden identifi ed by your OOIDputerizcd biUing list. You will be asked to
revi ew each patient 's record while being interviewed by a research nurse who will
complete a questionnaire . The time will vary depending on the number of cases
identi fied.
Benefi ts Which the Subject May Receive
Physicians will receive an honorarium ofS20.00 for each case reviewed.
Liability Statement
Your signatu re on this fonn indicates that you have wtderstood to yoW'satis faction the
information regarding your participation in the research project and agree to participate as
a subjec t. In no way does this waive yout legal rights nor release the investigators,
sponso rs, or involved institu tions from their legal and professional responsibilities.
Other Relevant lnfonnation
Your identi ty and the identity ofyour patients will remain confidential. Unless required
by laws or other regulatory agencies only Dr. Ford Bursey and his research ass istants will
have access to the data identifying subjects by name .
___ _ _____ _ _ ~' the undenigued, agree to my
participation in the research study desaibcd.
(Signature of Participant)
(Sign ature ofWitnc:ss)
To be slgaed by mvesdl: ator
(Date)
(Date)
To the best ofmy ability I have fully exp lained to the subject the nature of this research
study . I have invi ted questions and provided answers. I believe that the subject fully
understands the implications and voluntary nature of the stud y.
(Sign ature of Investigator)
Phone Number
(Date)
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PILOT STIIDY QUESTIONNAIRE:
AN EDUCAn ONAL lNTE RVENT10N TO IMPROVE THE PRESCRImON OF
UPPER GI DRUGS
Questionnaire for Doctor Interview
DATE OF INTER VIEW:
PATIENf INFORMA nON
PREVIOU S UPPER GI DIAGNOSIS ,] (SPECIFY) YES 0 NO 0
Patient Num ber Se:t: I . Male
2. Fcmale
Dale o f Birth :
I I
DDIMMIYY
Dale of Previous Descri ption o f Previous Diagnos is TrealJncnt
Diagnosis (" mak e DOle ofany lifCSfyle
(DDIMMIYY) chan llCSrecommended· · )
I I
I I
I I
I I
I I
I I
I I
I I
I I
I I
I I
I I
PREVIOUS INVESTIGATIONS :
Type of Investigation Date of Resu lts
Investigation
(DDIMMIYV)
1 Endoscooy I I
2 I I
I Up 01 Series I I
2 I I
3 I I
4 I I
Ultrasound of the Gall Bladder I I
Gal l Bladder Series I I
Barium Enema I I
EKG,Stresstest,etc. .. I I
Other (specifY) I I
HAS THE PATI ENT HAD PRE VI OUS UPPER 01 SU RGERY'! YES 0 NO 0
CO NCOMIT ANT MEDICATIONS:
ONg Start Date Dosage Freq uenc y Ongoing
(Generic Name) (DDIMMIYY) (YIN)
I I
I I
I I
I I
I I
I I
I I
I I
Is the patient compliant '!
Is the pati ent on any other-fonn of treatment ?
Yeo D No D
Yeo D NoD
HISTO RY OF PRE SENT ILLNESS
Signs And Symptoms (Circ le all those app licab le):
I . Retrostema.l pain
2. Bloating
3. Dysphagia
4. Substemal.pain
5. Heart Burn I Dyspepsia
6. Coughin g
7. Bleeding
8. Nausea
9. Watcrbrash
C URR ENT DIAGNO SIS:
TREATMENT:
10. Epigastric pain
II . Belching
12. Odynophagia
13. Early Satiety
14. Sensa tion ofa lump in throat
IS. Chcstpain
16. Stomach burning
17. 0Iha" ('P'ci'Y)
DATE:
Non-Pharm aceuti cal Action Taken (Circ le al l those applicable):
I. Elevate head at night
2. Avoid chocolate
3. Avoidcaffcinc
Pharmaceutical Action Taken :
4. Avoid acidic foods
5. Stop smo king
6. Discontinue NSAID
7. Weight loss
8. Avoi d alcohol
9. Other
Drug Start Date Dosage Freq uency Durati on Indication
(Generi c Name) DDIMM!YY (weeks)
I I
I I
I I
FOLLOW UP INVESTIGATIONS:
Type of Investigation Date of Investigation
Endoscopy I I
Upper Gl Series I I
Ultrasound of the Gall Bladder I I
Heli cobacter pylori antibodies test I I
Referred to Specialist (specify) I I
Other (Specify) I I
ACCOMPANYING OR UNDERLYING DISEAS E OR CONDmON WHICH MIGHT
HAVE INF LUENCED C HO ICE OF lREATMENT (CIRCLE TIl OSE APPLICABLE):
I . Ability to pay
2. Underlying Disease (specify duration and severity)
3. Allergi es (specify)
4 . Other (speci fy)
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Crite ria for D••pOlis ad TreabDe.t of Upper GI Disorden
The vast majority of all upper gastrointestinal symptoms are classified under three
diagnoses ; I. gastroesophageal reflux disease (GERD); 2. nonuJcer dyspepsia (NUO) ; and
3. pepti c ulcer disease (PUD) .
Gastroesophageal reflux disease varies in severity. This spectrum ofseverity
encompasses very mild GERD, no aPlJlltCl't inflammation, to very severe. involving
stricture fonnalion and ulcerat ion." ... The cardinal symptoms of this condition are
heartburn, classi c burning sensation in the low retrostemal area that usual ly radiates up to
the neck, and acid regurgitation, the perception ofretrograde flow ofgUlric co ntents into
the phamyx . Other symptoms include nonspecific chest pain, dysphagia, water brash.
and respirato ry symptoms."
Nonulcer dyspep sia (NUn) is a recurrent pain or discomfon in the upper abdomen .
The sym ptoms of nonul cer dyspepsia include (I ) immediat e postprandial pain . (2)
postprandial fullness. bloa ting or distension, (3) earl y satiety , (4) postprandial nausea and
vomiting, and (5) belching, gas or flatulence .' s GERD and NUD can co-e xist as pan of a
more diffuse disorder of gastro intestinal motility.9691
The manifestations of peptic ulcer disease and nonu lcer dyspepsia are comparable. In
fact, it was suggested by Spiro in 1974 that ulcer and nonuJcer dyspepsia are the same
disease and that the ulcer is incidental and transient." 9'l 100 Since then it has been
established that the etiology of thesetwo disorders are different . Unl ike nonulcer
dyspepsia, peptic ulcer disease:is associated with the presence ofacid and Helicobacter
pylori or NSAID USC. IOI peptic ulcer disease usually peeseets as chronic , intermittent
epigastric pain . It is necessary to perform an investigative technique. endoscopy or
radiography, to accunJtely diagnose the presence of an ulcet"8.tion. '~ lOJ 10-
Criteria (or Treatment :
Effective treatment and accunte diagnosis ofuppel' gastrointestinal problems requires the
physi cian to obtain a thoro ugh medical history oftbe patient. A patient history should
include an explicit description of the symptom, suchas its OCCWTenCe, location ,
periodicity, and associated factors , any past gastrointestinal disorders or surgery , and any
systemic illnesses which may affect the stomach.un Any alarm symptoms, including
anemia, weight loss and severe abdominalpain. may indicate an organic disease or a
more serious gastrointestinal disorder that would require immediate treatment and careful
investigation." A rational approach must be developed which will allow them to
determ ine the cause of these symptoms. If, they are caused by peptic ulcer or
malignancy. immediate treatment is necessary. Although gastroesophageal reflux disease
and nonulcerdyspcpsia an: not as critical, the patient's qwlity oflife will be impeded and
signi fican t morbidity may occur ifthesc disorders are treated inadequately or not at all.
The treatments recommended for gastroesophageal reflux andnon-ulcer dyspepsia are
similar. Initial trutmeRt involves life style modifications ± OTe therapy ." An
inadequate response justifies a presaiption ofH2 receptor antagonists, or prokinetics if
the gas-bloat syndrome is present . The guidelines used in this study require that the
patient be referred to a gastroenterologist if symptoms persist. If an investigation
establishes a diagnosis of esophagiti s. treatment with proton pump inhibitors has proven
to be clinically superior to Hl receptor antagonists. Sol1001101101
Once it has been ascertained through an upper GI investigation, e.g , endoscopy or VGI
series , thaI peptic ulcer disease is present the treatment is unequivocal as previousl y
mentioned. Recentl y it has been shown thai:over 90"/0ofnonmaJigrwu ulcers, not
induced by NSAIDs, arc associated withH. pyiori.lO'JIIOIIl Ilr Due to this high prevalence
of Heticobacter pylori infection of ulcer patients, eradication therapy is the recommended
treatment.101 III II. 11$ Although there has been some discussion on the use ofantibioti c
based therapy for the treatment ofNSAID induced ulcerations it has not been proven to
be mo ve effective than treatment with a pro ton pump inhibitor. Le. omepnzole.lll llJ
Guidelines fo' T,eatJrrent:
I. First line treatment should be lifestyle modifications and/or over-the-counter
medications (LSMlOTC).
2. Any patient over the age of 40 presenting with symptoms of an upper GI disorder
should be referred for an investigation, if no investigation bas been performed in the
past .s years . They should betreated with the most recently effective maintenance
therap y is prescribed (short tenn treatment) and patient is referred for an investigation
3. If symptoms/investigations show that GERO is mild CO moderate, H2RAs or
prokindics are equally effcctiveand could be presaibed !fLSM and OTe therapy
were ineffective. However the cheapest drug is the most cost effective choice .
4. If alarm symptoms are present (i .e. anania, weight loss , aspiration, dysphagia) the
patient should be either referred for an endoscopy immediately, or if an investigation
has previously been done, then the most effective treatme:ot should be prescribed.
Crireria for Treatment with Proton Pump Inhibitors
Peptic ulcer disease ""PPI + antibiotics (He/icobtJcter pylori mld.ication therapy)
NSAlD induced ulceration : discontinue NSAIDs,. ifpossible, and treat with a PP J.
Iferadication therapy has been prescribed previously and the patient n:tums within 2-
3 wee ks with recurrent dyspeptic symptoms, a PPI should be prescribed and a further
investigation performed
Ifsym ptoms/ investigations show that GERO is severe then a PPI should be
prescribed
Criteria (or Treatrru!ntwith PPli- (cont '4)
Barr ett 's esophagitis and severe esophagitis are permanent cond itions, therefore any
documentation oftbese conditions requires that the patient becreated with a PPI
GERD complicated with stricture
Ulcerative esophagitis wammts long term treatment
If th e patient is nonresponsive (persistent symptoms for I month or recurrent
sym ptoms for over 2-3 months) to H2RAs, then a prescription ofPPI is deemed
appropria te.
Appendix D
Description ofDn. ElI'ecdve ia the Treatmellt of Upper CI Disorden
Proton pump inJtibitors are the newest drugs usedin upperGI diseases. A commonly
used proton pump inhibitor (PPI) is Omeprazole, which is a substituted benzimidazole.
Thi s compound is a weak base that becomes protonated in the acidic environment of the
parietal cell , and it is this active form which binds inevenibly to the W .K--ATPase
(proton pump) enzyme. This inhibitory complex blocks the final step ofgastric acid
secretion , thus preventing basal and stiJIluiated acid secrencn.!"
Histamine H1 receptor antagonists (H2RAs) are competitive antagonists for the
histamine H1 receptor located on the basolatcral membrane of the parietal cell.'loO 111 By
binding to the H1 receptor , thesecompounds prevent histamine from stimulating gastric
acid secretion. However, the parietal cell is also stimulated by acetylcholine and the
hormone gastrin. 'This makes it possible for the parietal cell to bestimulated despite the
presence ofan H2 receptor antagonist, i.e . meal stimulated gastric secretion. An
illustration of the mechanisms of action of proton pump inhibitors and H1 receptor
antagoni sts is shown after the remainder of upper GI drugs are discussed.
Prolcinetic agents are compounds which enhance contractile force andaccelerate
motility throughout the length of the gastrointestinal tract.1191l0 The most commonly
prescribed prolrinetic agent is cisapride. a third-generation prokinetic agent. Unlike the
first and second generation prokinetics, cisapride is devoid of any central depressant or
antidopaminergic effects . The rationale for this fonn of therapy is 10 alleviate defects in
the gastrointestinal neuromuscular activity by stimulating acetylcholine release, which is
mediated by specific enteric nerves . This agent results in increased motility and clearing
peristalsis, and increases lower esophageal spbincter pressure.
Antibiotics are essential elements in tben.py used to eradicate Hettcobacter pylori. It
has been determined that if an ulceration is not related to NSAID use, then H. pylori
infection is a significant causative factor for peptic ulccrdiscase.1OO To date: tripl e therapy
is the most effective form oferadication therapy ofwhich there are two styles :
Classical = bismuth containing compound + 2 antibiotics
Newer " proton pump inhibitor + 2 antibiotics
The more frequently prescribed newer fonn of eradication therapy involves a shorter
treatmen t regime ( I week vs . 2 weeks), which increases patient compliance. and there are
less side etfCClS.ll2
Appendb: E
Improving Prneriptio. of Upper GI Drup: Study Desip
Reseueh Questioa
Is it pos sible to improve the appropriateness of prescription ofdrugs for upperGI
disorders, primaril y by reducing the underutilization of proton pump inhibitoo, through
the implem entation of an educational intervention?
Researcb DesigD
A randomized controlled intervention study involving community based fmil y
phys icians. The presence of the control group will allow any effect that coimevennon
(e.g. emergence of new guidelines! policies during the trial) had on the results 10be
asses sed. The design of the study involves two phases :
Phase I : expose the study group to the in1eTVentioo(. ), which is aimed at
enhancing the appropriateness of dNg prescription by the phy sicians
Phase II: measurement of the physicians' prescription patterns after the
intervention has been completed.
IntuveadoD
The continuing medical educational module, on the long-term managcmem ofpcptic
ulcer disease, ga.suoesophageal reflux disease and nonulcer dyspepsia, will beihe basis of
the interven tion. The azticles selected through the literature review dcmonstntcd that the
most appropriate and effective form ofeducational mteeven ticn involved one-en-one/
face-eo-face visits by either a pharmacist: or physician.l2ll l21
The edu cational intervention to be implemen ted in this study will involve:
(a) a vi sit to eachphysi cian 's office by. phannacist to providcdetailing:on the
appro priate treatment of gastrocsopbagc:a reflux disease , peptic ulcer disease and
nonulcer dyspepsia and,
(b) a gro up educati onal dinner leennewiU be given by a gastroenterologi st.
The co ntent of both the visit by the pharmacist and the dinner lecture will follow
diagnostic and treatment guidelines and education material that is approved by the
Canadi an Associati on ofGastroeQtcrology .
Primary Outcome: Uadcnltilizadoa of Proto. Pump labibiton
Th e underutilization rate of proton pump inhibitors refers to patien ts who need a PPI
but are not prescribed one. This outcome measurement has been chosen partly due to thc
curren t restriction by thc provincial drug program limiting the prescripti on o f proton
pwnp inhib itors, which may lead to undcrutilization in subgroups of patients who may
benefi t from these drugs , e.g . patients with pepti c ulcer disease and severe G ERO.
Secon dary OulleOmc: UnderlOverulillzatioa Rain or aU Upper GI Drugs
Under and ovmrtilization rates of all classes of upper GI drugs including H2 recept or
antagonists, proltineti cs, cytopretective agents, antibiotics, and antacids .
Sample sin
There are two manners in which the sample size can be calculated and issues arose for
both. These issues were discussed in chapter VI.
Sam ple S ize # I
One method would be to categorize physicians as having acceptable underu rilization
rates 01'"DOL This avoids the problem of aw.mllng independence of deci sions for like
cases by individual phys icians when each physician ccembutes more than one
therapeutic:decision to the results . Such an assumption would be unlikel y to be true
beca use physicians are more likely than not to make simi larly correct 01'"incorrect
decisio ns about patients with the sametype:s of problems. In any case it is the physician
who is the unit of randomization and not the prescription. so one cannot j ust calculat e the
grou p average underutiJization rate fer PPI's ignoring how man y case are contributed per
physici an. An arbitrary cut point of <200/0underu tilizati on could be defined as
acceptable. The pilot stud y suggests that the proportion of phys icians with an
underurilizati on nne o f <2 ()O/.should beapproximately 33% before the interv ention . If
the intervention is successful it is hopedthat the proporti on of physicians with an
underurilization rate of <20% will increase to SS% in the interven tion group , but will
remain at ))0/. in the control group.
u = O.OS
~ ·O.2
Two independent groups · Proportions
one-tailed hypothesis will be used since we are determining if an intervention had a
positiv e effect on th e study subjects. whereas if its implementation was unsuccessful
the costly nature of the interven tion would prohibit its future usc.
The calculati on of sampl e size is based upon the results of the pilot study, with the
underu tilization rate as the basis of the arbitrarily assigned score .
n/grcup e 2( tz, + Ze) I (2sin-1 ,;-;:- • h in·l ,;;;;) lz
n/group e 2( (1.65 + 0.84 ) I (2sin·' ..f'033 _2sin ·1 .J0.55 ) ]1
nlgroup • 6 1 phys icians are required for both the intervention and contro l groups.
Using this sampl e size £onn ula for two independent groups (proportions), 6 1
physicians will be needed in each study group . An issue arising with this approach is
how many cases sho uld each physician treat to pro vide a reliable refl ection o f hislher
prescribing practi ce . From the pilot study it was shown that of the 15 patien t chans
per physician included in the study, there were on avera ge 4 patients who needed a
PPI (27%). If an indi vidual physician were found to prescribe PPI 's to say 4 of 5 who
needed them, the co nfidence interval around the observ ed inappro pri ateness rate of
20% would be very broad. Thus one could not use these results to accurately classify
that individual physi cian . However, misclassification into acceptable of unacceptable
undcruti lization groups should be unbiased and therefore results for the group should
be interpretab le. If 122 physicians were available for the study, a total of2 196
pati ent charts would have to be reviewed by the research team to ensure tha t about 5
patients needing PPI's were seen by each physician. However, there are on ly 110
physicians located in the:St. John 's!Mount Pearl region and it may not be feasible to
obtain consent from all ofthem .
Sample Size #2
An alternative method that would also get aroWldthe independence of decisions made
by doctors, could be basedon a comparison of the mean percent inappropriate
underutilization ofPPl's across physicians in each group. For this method the proportion
undemtilized would be tim determined for eachphysician and then the group mean and
standard deviation for this measure would be calculated. This approach depends upon the
assumption that the underut:ilization rates are normally distributed within each group .
a = 0.05
~ ·O.2
Two independent groups - Means
one-tailed hypothesis will be used since we are determining if the intervention had a
positive effect on the study subjects, whereas if its implementation was unsuccessful
the costl y nature o f the intervention would prohibit its future use .
In the pilol study , the mean underutilization rate of proton pump inhibitors by the
physicians studied was 39% . However, within an observed range of 0 - I()()O/... the
rates per physician wen: not nonnally distributed about the mean . However, the
sample size in the pilot was small . If one assumes lhat a larger studywould also
observe a range ofunderutilization rates ofo-IOOO/e. and that the rates would be
nonnally distributed within this range, then one could reasonably infer that the range
would encompass 3 standard deviations on either side of the mean. This would imply
a standarddeviation ofabout one sixth of 100-10, or about 17%. If, as suggested by
the piJot data, the undennilization rate will be approximately 39"10 in the control
group , andone wishes to be able to show a fall to 29"10 in the intervention group .
nlgro up '" 2[ (Z.. + Zp) a /AY
nigro up '" 2[ (1.65 + 0.84) 17/10]1
nlgro up "' 36
As with method #1 above this approach also requires that one observe the percent
inappropriate WJderutilization ofPPl's perpbysician. Yet again one is faced with the
problem of determining how many casesneed to be reviewed per physician to determine
tha t rate . In this case one would need 10 examine many more than 5 cases needing a PPJ
as otherwise the proportion underutilizedwould be constrained to lie at 0, 20 , 40, 60, 80,
or 100% only. This would make it impossible 10 determine whether there was a nonnal
distribution of undendiliza tion rates within a group. Therefore one might wish to
exami ne enough charts 10 find 10 cases per physician where PPJ's were ind ica ted.
With 110 physicians in the region it should be feasible to cnroll80 of them in the
stud y. On average each physician would need to provide 10 cases where a PPJ was
Indicated. The pilot study suggests that this would require review ofan average of 38
charts per phy sician for a lotal of 3,040 charts .
Rapdomizlldoa
This study will be a randomized co ntrol trial , which is the standard approac h to
eval uatin g the effectiveness of an interventioo. Physicians , woo have agreed to
parti cipa te, will be randoml y allocated to a control 01" intervention gro up based upon
nwnbers in sealed envelopes . An individual who is independent ofthi s stud y will
confidentially assign an env elope to eacb subject. Although some contamination ma y
occur within the control group as a result of discuss ions between ph ysi cians who work
within the sam e practice , it was determined that to randomize physicians by gro ups w as
not feasi ble. The number of practices that would have to be randomized to ensure
statisti caJly signifi cant resul ts exceeds the nwnber ofpract:ices that are avai lable for
randomization within the St. JOM 's - Mt. Pearl area. Thi s number of avai lable prac ti ces
will also decrease when 8CCOWlt is taken of the numberof pbys icians who will not
consent to parti cipate in the study, causing a further reducti on in th e feasibility of
carryi ng out suc h a randomi zation .
Method
Aft er recei ving the consen t from the physi cians (N""SO) to parti cipate in the study the
research team conducting the study will random ly al locate the ph ysici ans into the con tro l
and interv entio n JI'OUps. The intervention group (N - 40) will receive a phone call from
the investigator to request thei r parti cipa tion in the contin uing education sessions and also
to request that they not discus s what is covered at these sess ions with their peersdue to
the nature of the stud y. Subsequentl y . pbannacist will visit each ph ysi cian in the
intervention group for a one-on-one infonnation session on the appropriate treatment of
upper 01 disorder's.
Six months after the educational intervention is comp leted, a research nurse will visit
the practices ofal l 80 physicians., and review the MCP billing codes o f the patients seen
within the previous 6 months to identify those seen for upper gastrointestinal disorders .
Of those patients the most recent 17 cases wiU be identified for patient specific data
abstraction which will result in a total of 1360 cases which will be included in the data
analysis. Predefined diagnostic and treatment data will be abstracted from the patients '
charts using a standardized questionnaire (AJJPeDdix B). Subsequent to this data
collection, each physician will be interviewed by theresearch nurse to obtain further
infonn ation about the patient which could not be detemrined from the chart . In order to
determine the effects of the educational intervention and eliminat e as many confounders
as possible, the data collection for both the control and interventi on groups are to be done
throu ghout the same time period . This is based on the asswnption that all doctors will
recei ve the same amount of background education from the pharmaceutical companies
and that seasonal variation in prescribing practices occurs and must also be controlled for .
To check whether the results obtained have been affected by external confounders,
info nn ation will be obtained from the International Medical Systems (lMS) Canada data
so urce which will show the overall prescribing patterns throughout the period in which
data collection was done . This external validation will detcnninc whether seasonality or
any restrictions in the drug "formulary had an adverse effect on the prescribing patterns of
physicians at that time.
Due to the large number of patienc chatcsit would be wuasonable to assume that an
expert panel comprised of a gastroenterologist, epidemiologist and pharmacist would be
able to revi ew all 1360 cases within a limited amount oftime, therefore this data will be
reviewed by the research team. Following predefinedaiteria each patient will be
ass ign ed a diagnosis and treatment and through comparison with guidelines the
appro pri ateness of the ph ysicians ' prescribing practice will be assessed . In order to
ens ure that the assessment of these ca.ses was consistent and correct every one in 10 of the
cases where it was determined that PPl s were underutilized and any cases where a
di fference between the research team and the prcscn"bing physician exists will be
review ed by an expert panel.
Statistical Allalylb
All data will be analyzed with SPSS , • statistical computer program . The frequency of
prescription for each drug group will be calculated and the percentage of inappropriate
prescriptions for each physician will be calculated first, followed by description o f the
distribution of these rates by group. The inappropriate presaiption frequencies will
dem on strate both inappropriate overutilization (those who received the drug and didn ' t
need it ) and inappropriate underutilizatiOD (those who needed the drug and didn 't receive
it ) for ea ch drug group. Confidence intervals will be ca:Jculated for the difference in
proponions between the control and tatervennoe groups . A t-test for independent groups
will be used to compare the mean underu tilization nue ofPPl' s between groups.
The hypothesis (H.oJfor this study is that an educational intervention will increase the
physicians ' adherence to recommended guidelines, thus leading to a difference in the rate
of inappropriate prescribing by phy sicians in the control (C) and intervention (I) groups.
Ho:C<?: 1
H,, : C <I
The invol vement of two assessment teams (research nurse and research panel) requires
the asses sment ofinterra ter reliability with the use of lcappa scores. This statistic allows
for nominal scale assessment of the level o f agreement among the tw o evaluators .
Excellent agreement beyond chance is considered to exist when kappa is greater than
0.75, while values between 0.40 and 0.75 represent fair to moderate agreement.l:U
Eff«th'eaess of the laten-eadon
In a parallel group rando mized trial changes from baseline seen wi thin the control
group are assumed to result from chance, regress ion to the mean, contamination , or
external factors other than the intervention (e.g. drug compan y detailing, changes in
governmental reimbursement policy ). Unfommately, if the changes in the intervention
group are equal to those seen in the co ntro l group the null hypothesis can not be rejected
and it could be difficult to differen tiate an ineffective interventi on fro m contamination of
the control group, or the effect of strong external factors. Howe ver, to help iden tify these
problems, data will be obtained from an cxtemal50UlCe (c.g. lMS) to determine the
overall prescription rate ofupper GI drugs within the region before and after the
interv ention.
Ethics
The family physicians will be asked to sign a consent form (Appendix A) ro show thar
they agree to panicipate in this study and !hat they consent to have infonnation obtained
from their patients ' charts and a physician interView to be usedin the analysis. The
consent form will explain the measures which will be taken to ensure that the
confidentiality regarding the physicians and their patients will be maintained. Although
infonnation pertaining to patients will be used in this study, the consent of each patient
will not be obtained because: any information capable of identifYing a patient will not be
collected.
Appendix F
FACUL1Y OF MEDICINE
MEMORIAL UNIVERSIn' OF NEWFOUNDLAND
ST. JOHN'S . NEWFOUNDLAND AlB 3V6
TffiE: PUot Study : AJldb60tk Use in the CoIlUD-mty (phase I)
INVESTIGATORS: Dr. J. Hutchinson. Dr. P.S. Parfrcy
SPONSORS: Provincial Dept. ofHcahb.
AbbottLaboratories Ltd.
B_Inc.
Glaxo Canada Inc.
Pfiza-Inc.
You have been asked ID participate in • n::sc:arch study. Participation in this study is
entirely voluntllly. You may decide not 10 participate or may withdraw from the study at
any time. Confidentiality of information concerning participants will be maintained by the
investigator. Tbe investigator will be available during the study at all times should you
have any problems or questions about the study .
Purposeof study :
This study will describe the current medical man8IlCD1CUt of infection related illness .
Baseline data will be collected on patients with infection related illness so that population
rates can be calculated for a) the bwden ofinfedion in the commWlity b) bacterial infection
requiring antibiotics c) reasons for antibiotic prescriptions
Description ofprocedu:res:
Under your supervision a resean:h nurse will come ID your office 10 review all cases seen in
your practice on the two prmousdays. You will decide the day of the week that is best for
you but you will not know which week. Data will be «tracted from the charts of patients
who were seen for infection related illness . You will be interviewed by the research nurse
so that more data can be collected on these cases (20 in all ). Your ieteview will last
approximately S minutes for each case reviewed,
Those patients with infection related illness will recei ve a letter from you explaining that
you we participating in a resean:h study . lbe Jetter will also explain that a research
nurse/assistant will contact them by telepbooe to ask for their participation They will be
advised that they may decide to participate or not parti cipate without affecting their normal
treatment. If they are willing. they will be asked questions about their illness w ing a
standardized extraction fonn. Their interview will last 5 minutes .
Dumtion of subjects participation:
The study will be conducted from May 1997 to June 1997. You will be asked to designat e
a period of time from your practice to review 20 cases oflnfection related illness occurring
in yo ur practice during the prn10US two days . 1be time ofme interview will be I hour to I
II2 hr5.
Foreseeable risks, discomfons. or inconvcnimocs:
Each case reviewed wil l take approximalely 5 • 10 min utes of your time.
Liability Disclaimer Statement:
Your signature on this fonn indicates that you hav e wxtemood to your satisfaction the
infonnation regarding your participation in the research projectand agree to participate as a
subject. In no way does this waive your legal rights nor release the investigators, sponsors,
or involved institutions from their legal and professi onal responsibilities.
;;""·-'-",~pa""n"".o-o~in""lhe-=-""h-""""~-d~"","-'-ibcd~.----, the undemgncd, agree to my
An y questions have been answcrrd and I undemand what is involved in the stud y. I realise
that participation is volwnary and that there is no g\W8Ittce that I wil l benefit from my
invol vement. I acknowledge that a copy of this form has beengiven to me.
(Signature o f Participant)
(Witness Sipaturc)
To be:signed by investi@!lOI:
(Dot<)
(Date)
To the best of my ability I have fully explained to the subject the nature of this research
study. I hav e invited questions and provided answers . (believe that the subject fully
understands the implications and vo lun tarY nature of the study.
(Signature of lnvesti gator )
Phone Number _
If Ap pro priate :
(Signature ofMine r Participant)
(Age-l
Relations hip to Panici pant Named Above _
AppeDdilG
Use of ADtibiodcI fa die Commwt)'
""_pbJc Dota
CaseNum bc!"
Dat e Pt Visited __t__'_ _ Doctoe s
y M 0
Patient #__
First Name Last Neme _
Mep
Address Te'_(H) _
Te'_(W), _
Postal Code, _ Family Physician _
(This fonn will be filed separatel y from questionnaire and intervjew data. Onl y the case:
number will be used 10 iden tify the patients on the questionnaire and interview data forms.)
Cue Namber _
(YMD) Doctor* __ PatiftltN __
Age: ----->TS_mos So: I. Male. 2. Female New 'adea t I. Yes 2. No
Relevant Past Med1caI Bktory
Pregnancy. I. Yes 2. No
Diabetes .... I. Yes 2. No
COPD ... I. Yes 2. No
Renal lnsuflicicncy 1. Yes 2. No
CHF 1. Yes 2. No
Antibiotic Al lergy 1. Yes 2. No
Smoker .. I. Yes 2. No
Prior Occurrences I. Yes 2. No
Culture Taken I. Yes 2. No
Other I. Yes 2. No
Usual Tx
Response
Other Comments
!!!!Jas per chart)
Code
CumDt MedkatioDt
Current / Reccnt AnbDiotic Treaunem: I . Yes 2.No
Start CUlTftlt Dntp ..... Dun... Slop Date Comp Uaac:e
Da..
RESPIRATORY CLASSIFICATION SYM PT OMS
DIAGNOSIS
SEVERITY 2. chills
UPPER 1. mild 4. congestio n (where,
I. rhimts 2. modaale amount)
2. sinusitis 3. SClICtt
3. otitis (type) 5. cough(ho w long,
4 . laryngitis ACUITY productive)
5. pharyngiti s I. acute
6. 0 ", " 2. chronic 8. discharge/drainage
3. acete on chro nic (where, type. amount)
9. dyspnea (describe)
PRO BABLE MICRO
LOWER ORGANl SM(S) l Lfever
7. AECO PD I . virus 12. hemop tysis
8. bronchitis 2. bacteria 17. nodes enlarged
9. bronchiectasis 3 o<he<
- - -
20. pain (wtJcrc., type,
10. pneumoni a (community severity)
acquired, mig home)
I I . cystic fibrosis
12. whooping cough 21.nleslcracldes
13. othc:!' n . rbonchilwhee:ze
24. rigor
26. sputwn ( co lour,
amount )
GENITOURINARY CLASSIf1CATION SYMPTOMS
DIAGNOSIS
I. UTI SEVEIUlY 2. chills
2. cystitis 1. mild 8. discharge
3. prostatitis 2. modente (whcrc,colcur, amount)
4 . pyelonephritis 3. severe
5. orchitis 10. dysuria (describe)
6. epididymitis ACUITY
7. epididymoorchitis I.""""
8. PlD 2. chronic Il.fevc:r
9. urethritis 3. acute on chronic 17. nodes enlarged
10. cervicitis (wh<re)
II . other PROBABLE MICRO 20. pain (where, type,
ORGANlSM(S) severity)
I. virus
2. baclcria 24. rigor
3.otbel'
---
28. urgency/frequency
.....
SKIN /SO FT T ISS UE CLASSIFICATION SYMPTOMS
DIAGNOSIS
I . abscess SEVEIUlY 8. drainage (where,
z. bite I . mild type,amount)_ _ _
3. celluliti s 2.modente
4 . chicken pox 3. severe l Lfever
5. diabetic foot 14. lesion (where, type)
6 . dccubitousulcer ACUITY
7. facialery1ipelas I."""" 20. pain (where ,
8. h"",,(gmital) 2. chronic:
-...verily)
9. herpes (simplex) 3. aeute on chronic
10. impetigo
II . shing les PROBABLE MO 21."""""
other I. virus 27. swelling
2.bactcria oth~_ _ _
LOCATION 3......
OTHER DIAGNOSIS CLASSIF1CATION SYM PT OMS
I. bone jo int infection SEVERITY 8. draina ge (wheR. type .
2. gastro-en tcritis Lmild amount )
3. meningitis 2. modeme
4. intra abdominal infection ).~
S. other I I. fevel"
ACUTIY (lem perature)_ _ _
I. 0CUle 11. nodes enl arged
2. cfIronjc (wh«<)
3. acute on chroni c
20. pain (wbere . type.
PROBABLE MO(S) severity)
I.vi:us
2.bactc:ria3. _ _ _ __
22. redness
2S. seizure
27. swelling
o!he<
Sample Co llected I.Yes 2. No Date TYP" _
Resul ts _
A) Antibiotic prescribed I. Yes 2. No
~~~§'-~.....J~
I. Medical IndicationU_
I
2. PatieutIPamrt Expectation or danand
No influence
I
3. Time Constraint
No influence
I
Very-Clear
5
SttongInfluencc
5
Strong lnfluence
5
4. Sense that patient would attend another physician if they did DOtreceive an
antibiotic prescription
No influence Strong Influence
I 5
B) Over the COIlIIter TrabDeDl
C) Referral
D) Advised
Additional COIlllHllU:
I. Yes 2. No (specify)
I. Yes 2.No (specify)
1. Yes 2.No (specify)
Appeaclli.1
Date
Dear ~-~
Our clinic is participating in a study which is being conducted by Dr. 1. Hutchinso n, a
specialist in infectious diseases, at the Health. Scienocs Ceetre,
We are interested in leamingrnorcabout the rate ofinfcction in the community andthe
reasons for antibiotic prescriptioDs. In orda' 10do this Dr. Hutchinson bas asked all fami ly
physicians in the 51.John 's area 10 identifypetiems treated for infection milled illnesses
such as chest infections, urinary tract infections, skin infection, etc . I am asking yo u to
participa te because you hada recent visit 10myelinic for an infeaion relllled illness. Your
partici patio n is entirel y voluntary. You may pcticipatc or not participate without affecting
yournonnaI treatment
A researc h nune will con tact you by te lephone:. If you arc willing 10 panicipatc you will be
asked some questions about the symptoms you bad at the time of your clinic vis it and if
they have improved. You will also be asked some questionsabout what antibi oti c treatment
you ex pect ed, ifany, and if there wc:reothc:r factors that influenced your deci sion to visi t the
doctor that day.
If you do not wish to be contae1ed by the researdtnurse please complete the enclosed pre-
addressed stamped card andreturn it in the mail .
We hope that with your participation we can answer questions and learn more about the rate
of infection in the community and the reasons for antibiotic prescriptions .
Yours tIUly,
Family Doctor
IleviMd May I . I997
AppendbJ
CN
Oa,, __'__'__
y M 0
PII,.lkJa Number _
PatiealNumber
Why did you JO to the doctor? _
What were your symptoms? ( Usc symptom list to record sym ptom number and name.
give description when appropriate)
OaY'
DaY'
A),-,- o-c--,- o-c--=-~-,-=- --=-_
How long did you have it before clinic visit?
How long did you have it after clinic visit?
B),~_~_~~~~~~
How long did you have it be~ clinic visit?
How long did you have it after clinic visit?
____ DaY'
____ DaY'
C),~_~_~~~ _
How long did you have it before clinic visit?
How long did you have it after clinic visit?
Day,
DaY'
~~)-W-;Io-n-'-;di-;d -you-'-ha-,.- i"t be'--'-fo«---"'d~im~· '~vi-;sit?
How long did youhave it after clinic visit?
DaY'
D.Y'
Do you sti ll have symptoms ? I. Yes 2. No
Do=ribe,== = = = = = = = ==
If you were more than 2 hours joumcy from the nearest physician. would you have visitcd
lhe doctor wilh this illness ? 1. Yes 2. No
Before your visi t did you fed that your illness would be helped by an antib iotic?
I. Yes 2. No
Would you have beendisappointc:d if you had DOt received an prescription for and
antibioti c? I. Yes 2. No
Would you have sought the opinion of mother physician if you had not been given a
prescription for an antibiotic? I. Yes 2. No
Did yo u ask for. prescription for an antibiotic ?
Did yo u suggest the type of anblriotic that you felt was best for you?
I. Yes 2.N o
I. Yes 2. No
Did fearofmissing workIsc:bool influeoce your decision to visit the doctor? 1. Yes 2. No
Were yo u requimt by worltlschool (e.g . absentee DOte) to visit the doctor for this illness?
I. Yes 2. No
Prncriptioa
Do you have a drugplan
Did yo u expect a presaiption?
Did you receive a prescription?
Was your prescription filled?
App licable
Did you take it as prescnbcd?
(If no, describe.)
Did you ha ve side effects from dlug ?
No
Describe
FoUow- up
Ha ve yo u sought further treatment for the same
No
problem ?
Describe visits, treeunents aDdinvestigations.
I. Yes
I.Yc:s
L Yes 2. No
1. Yes 2. No
I. Yes 2. No
2. No 3. Not
2. No 3. Not App licabl e
I. Yes 2.
I. Yes 2.
Have you been hospitalized sinceyour clinic visi t? I . Yes 2. No
Describe• • _
Appeadb K
Critrrill IDr lll/«timn DisuM ClasijictltUHr
Rnpintory lalediOll.
Bacterial Pb.ryJlc'ds: [Approximately 80 · 90% of the time pbatyng:itis is not bacteriaJ
in adults and children .]
Children: I. Fever > 39.S °C
2. Pharyngeal exudate
3. Tender submandibular lymph nodes
4. PaJatine stippling
If 3 criteria are present thereis an 83% positive pRdietive value for stteptococcaJ throat
infection, and this increases to 88% if 4 criteria are present
Adult: I. Absence ofcough
2. History of fever over 38°C (101°F)
3. Tonsillar exudate
4. Swollen. tender anterior nodes
If only one criteria is present then neither a throat swab nor antibiotics are indicated ; 2·3
criteria present a throat swab is required andantibiotics started only ifculture is positive;
and if all 4 criteria present pcrricillin may be startedimmediately basedon clinical
grounds .
Acute Odds E:deraa: Symptoms include pain. itching. and a sensation offullncss in the
ear . Exudate. erythema. and edema may be seen in the canal.
Acute Odds Media : Inflamed car drum with fluid and one ofthe following : pain..fever .
irritability
Acute Slau.ltD:
Adults : I . MaxilllU)' toothaclJe
2. Poor responseto nasal decongestants
3. Colored nasal disdwgc by history or examination
4 . Abnormal transillwnination
Oth er symptoms include fever. malaise. cough, and headache or facial pain exacerbated
by bending forward .
Children: I. Nasal discharge (may bethin or thick and clear mucoid or purulent)
2. Daytime cough and may worsen at night
Th e child may not appear very ill and with low gnK1cfever .
Sinusitis may also appear as an unusually sever URI with severe symptoms (high fever .
purul ent nasal discharge.)
{Pers isten t symptoms ~ last more than 10 days and less than 30 days and have not begun
to im prove . The 10 day mark differentiates simple viral infection from sinusitis and the
30 day mark separates acute from subacu te and chronic sinusitis.}
Acute BroDChlttt: I . Producti ve cough with purulent sputum and wheeze
2. Nonproductive cough or colorless sputwn for > 5 days
80''/0of all cases of acute bronchiti s ue viral. however it is difficult to distinguish
between viral and bacterial pathogens since both result in purulent sputum .
Acute bronchitis in dU ldren is genenJ. ly always viral .
Acute EuarbadH. 0' CItnak BrNodJtb: I . lncrc:ucd cough and purul ent sputum
2. PadJosaUc:bacteriaon sputum culture
.50% o f AEcauti oon-bKtcrial. Chronic broachitis is definedcllnically as excessive
cough. productive of sputum ou moscdays. for at least 3 months a year durin g at least two
consc:cutive yees
PU UIDODia : I. Chills., fn-a" , cough with pleuri tic:chest pain, purulent sputum, rates .
and/or pulm onary conso lidatio n
2. Resp iratory symp loms with new infil~tes on chest x-ra y
Severe Plleumo.l.a : 1. Resptratory failure (pa OJ <60 mmH a· with exception of patients
wi th COPD who may be hypo xemic:without pneumonia)
2. Rc:spira1oryrme more than 30 per min ute
3. Sepsiswith evidc:oce of end organ dysfunction
4 . ExtrapUlmonary septic: complication
$. Cavitation or involvement ofmore than one:labean chest
radiognpb
Viruses an::responsible for pneumonia in the majority ofc:hild:rcn under.5 years o f age
WboopiDCCo.p: I. Cough with insptratory whoop
2. Cough > 7 days.,paroxysmal in nature
3. Cough end ing in spnea, vomiting or gaging for which there is
no other known cause
GenJtowiDary Tract IDfectioal
Ua~mpUQtedAcute Cysdtb: Urinary frequency, dysuria, lower abdominal-
suprapubic pain in females.,normaJ gcnita-urinary tract
CompUQted UTI : I. Symptoms ofcystitis with IUgh fever and chills
2. Includes obsttuction, chronic catheter, spinal cord injury , etc .
3. Symptoms ofUll. known Balita-urinary pathology
4. Symptoms of UTI in males
R~urreat Cystitis: I. RecunenceofsympiOlDS within I month of treatment
2. Three or more episodes per year
Asymptomatic UTI : I. Pregnancy
2. ~perative Benito-urinary proccdW'e5
Acute Prostatitis: I . Fever, acute perineal pain! discomfort! ± dysuria or frequency
2. Tenderproswe
Chronic Prostatitis: 1. Relapsing UTI in men
2. Chronic bacteruria with same organism
Chronic cases are less likely to be we bacterial prostatitis.
Epididymitis: lnnammation of the epididymis manifested by acute onset ofunilateraI
testicular pain and swelling, often with tcndcmcss of the vas deferens with erythema and
edema oftbc overlying skin. This docs not usually occur in prepubcnaI boys .
Note that when epididymis is accompanied by urethritis,. it is preswned to be a sexually
transmitted infection
Petvic:laf1aDuDatory DisnR: I. Lower abdontiDaI pain.,valPnaJ discharge ± dysuria.
fever , chills, DaUKa, vomiting
2. Cervical tC'Ddemes.s, 8dncul tendcmcss
Cenidtis : mucopwul ent or purulent ceni cal discharre. su.ptd. cbJamyd ia SCI"C'C'n
Uret.britis: dysuria, frequency, purulcm urethnI disdwJe, M e out G U. iDO'C'aSC' with
punni s [MCP as defined by: ( I) absence ofvagina1 itch, vaginal candidiasis, genital (W
rectal gono rrllea, (2) increase in pwmi s; (3) at least four of tbc following: history of
vaginal discharge, pwulent or mucopurulent secreti ons emanting &om the cervi cal os,
endo cervical piability .)
Skin aDd Soft T issue l.rec1iH..
Im pdigo: Focal erythema that prograses 10 pluritic vesicles, erosions, and honey-
co lored crusts. Lesions usual ly form on the face and spread locall y.
FoWculitis: Usual ly associat ed with an infected hai r follicle. Infectio us follicu litis
usually peesee ts as biger pustules (2-3mrn ). and there is more inflammation as
mani fested by . red halo and tendemcss. The lesions may beclustered rather than
scaneed,
CeUa Um : A superficial. spreading, warm , erytb erna«xas inflammati on of the skin .
AppeDdhL
Rnunb Qundou
What is the rate of antib ioti c:utilizati on within the SL lohn's - Mt. Pearl region '? Is it
possi ble to improve the uti lization of antibioti cs, by mluc:mg their ovcrutilization.
through the im plementation ofan educati ooal intervention aimed at improvi ng
physicians ' praa1biDg patterns'?
Rewarm Daip
A preIpost interVention trial is p1anDed involving family physicians who will receive
an educational inten' ention ttw focuses 011theappropriate:JftSCription of antibiotics in
the treatment of upper rcspira totY, urinary tract and akin and soft tissue infections . The
participatin g physicians will be assessed 6 months prior, at baseline, and 6 month s after
the interv entio n has been implemen ted. The base line assessmen t will determ ine the
overal l rate of antibiotic prescri ption within the SL lohn' s - ML Pearl region. Although
the prelpost desi gn will make it di ffic:ult 10differentiate the im pact: o f an interVention
from concomitant dlange whi ch may cccur in the bealth cue del ivery sector , an external
validati on oftbe data will be done which is disc:ussedin tbemetbod seaionofthis
protocol . Other confouDdcn whi ch may affect the results (e..a· seaso nal ity) WCfC
discussed in Chapta- VI.
Primary OUkollH
The appropriate utilization rate ofantibiotics (patient5 who needed an antibiotic and
received the optimal choice + patients who did oot needan antibiotic and did not receive
one, divided by the total number of patients seenby the physicians with infection) and
whether this rate is increased after the implementation of an educational intervention
which focuses on the optimal utilization ofantibiotics.
S«ondary OaCtolDe
The undcnatilization and ovcnatilization ofantibiotics will be determined and whether
the educational intervention was effective in reducing theserates . The ovcnatilization of
antibiotics is of specific importance because ofthe potential impact in promoting
selection ofantibiotic resistant organisms in the commwtity , together with unnecessary
drug-induced adverse events and costs .
Sample Size
The results obtained in the pilot study may not be reflective ofthe prescribing patterns
of the general population of family physicians in the St John 's . Mt. Pearl region. lbe
number ofantibiotic prescriptions that are filled each year in Newfoundland per physician
is much higher as determined by International Medical Systems (lMS) Canada database
than the rate seen in the pilot study . Since it is not possible to calculate a sample size
from these pilot study results it will be nccc:ssary to rely on results reported in a similar
interventi on study that was aimed at improving antibiotic prescription.
As a pannerofthis study and due to the importance of this study, the Newfoundland
and Labrador Departmenl of Health would like to enroll as many family phys icians as
po ssibl e from the SL John 's - Mt. Pearl area to ensure that the maximwn community
impact is made through thi s study . As a result it is hoped that 8()lJA,of fami ly pb)'5icians
in this area will agree to participate (N . 88). To determine whether-such a group would
be larg e enough to detect relevant changes in appropriateness of antibiotic prescription
one can use the experience of other investigaton as a guide .
A study that was performed in Australia by De Santi s et at (1994» )1 is very similar to
the stud y r have proposed. Their prc!post educational intervention study centered on
gen eral practi tioners and recommendations that were made in Antibiotic Guidelines.
Their measurement of approprialeDeSS of prescription was based en the physician' s
adh erence to the guidel ines and how the educational intervention impro ved their
prescri ptio n of appropriate antibi otics for IOnsillitis . Prior to the initiation of lhe
educational interven tion, prescriptions consistent with the guidelines were given to 52.90/.
and 60.5% of the control and intervention groups respectively. Using the average of
these tw o rat es, 56.7%, an approximation of lhe necessary sampl e size can be mad e based
upon the appropriateness of antibiotic prescription made by family physicians .
a = 0 .0 5
jl = 0.2
Tw o related groups _ Proponions
one-tailed hypothesis will be used since we an: daermining if the intervention bad a
positi ve effect on the srudy subjects. whereas if its implementation was unsuccessful
the costly nature ofthe intervention would prohibit its future use.
Due to the inadequate results that were obtained in the pilot study the rate of
appropriate antibiotic prescription as detcnnincd by De Santis et at. is used to
calculate the sample size . It is assumed that prior to the intervention the
appropriateness rate will be approximately S7V... however we wish to be able to
statisti cal ly detect an increase to 85% following the intervention .
nprcscriptionsprefpoSl -[(z... " n,;. (l - n,;.) + Z~ "1t1 (I-1tI)/(1t1. 7GJ)Jl
n prescriptions prcIpost - [(1 .65 " 0.57 (0.43) + 0.84 " 0.85 (0.15 ) ! (0.85 _0.57)]l
n prescriptions prcIpost =' 16
This number (N .. 16) would represent the minimum numbcrofantibiotic prescriptions
thai would need to be observed to obtain results which were statistically significan t. Th us
a planned stud y involving 88 physicians should have ample power to detect a chan ge of
this magnitude in appropriateness of antibiotic prescription. From another comparison of
the previously mentioned drug formulary data and the International Medical Systems
(lMS ) Can ada database. it was determ ined that approximately 25% of visits to a family
physician result in a prescription for an antibiotic. Therefore onl y a few chans per
physician wou ld have to be reviC\Vedto determine the impact of the interVen tion.
Me thod
The consent or 88 physicians IOpartici pale in me study will be obtained. The
pro tocol for this sndy is comprised of tbn:rcphases :
Phase I: baseliDcassessment of antibtotic pracriplions by family physicians
Phase H: physicians puticipatein llIIeducational intervention that is aimed at
improo.1.n,their~ 10 guidelines for anti-infectives
Phase HI: mneasuremcnt of antibiotic utiliution and physicians ' confonnity to the
guidelines
All family physicians (N .. 110) in the St. John 's ~ Mt. Pearl region (population
127,455) will be invi ted to parti cipate in the stud y duriD, • visit to their office by the
prin cipal investigator . A baseline assessment of antibiotic utilization will occur between
September 1997 - February 1998. This will involve a research nurse who will vis it each
physici an 's office at a ruadomI y selected time, and review the charts of patiena seen
within the pmtious 2 days. PaticntJ that Viae seen for infection related illnesses, such as
upper respiratory. urinary tnC1 or skinand soft tissue infccrions, will be identified and the
total nwnber ofinfca:ion related cases will be recorded.. However , relevant clinial da ti
will only be ntracted tium a maximwn of 15 consecutive charts using • revised
standard ized questionnaire (Appendix H). A thorough pati ent hiSlOrywill be record ed
w hich will inc lude all praenbna com plaints, resul ts of previous investigations, co-
morbid illnesses , allergies , corn:omitan t medications. and treatment prescribed.
Subsequently , each pb)"ici an wi ll be interviewed by • research nurse or research
assistant. once information pertaining to each patient bas been collected . Thi s interview
will allow for the rcsearcheT to obc.ainany additional clinical information thai: was not
recorded in the patien t' s medical ruord.
Following the basdineassessment an educational intervention will be imp lemenled
which wi ll invol ve face-to-face visits from a physician or pharmacist. The focus o f lhis
uuerveenon will be determined after the budioc assessment bas been comp leted and the
areas of concern regardinS anabiotic utilization are determined
Overal l antibiotic utiliza tion by quantity and type will be obtained from the
pharmacies within the 51. John's - Mt. Pearl region . These data will be collected for the 6
months prior to the c:ommcnccmcnt ofPhase I and also dwing PhaseII oflhis study,
which will demonstrate any shifts in prescribing behavior which cccurred at either o f
these times, allowing an extemal validation ofthc data coll ected. This extcma1 val idation
processwill al low the USCSSOB to be ab le to determine if the changes in presaibing
behavior are a resul t of extemal confoundcn. or are a direct result of the educa tiona l
interven tion that was implemen led throughout the study .
h was detennined through the pilot study that it is ft.aSible for a research team to use
casc-basc:daiteria to assign a diagnos is and apply guidelines 10determine the optimal
treatment for eachpaller'lL To ensure that this assessment is consistent and objective . the
expert panel will review one in 10 ofeases where it was determined that antibiotics were
overutilized .
Inten-ention
The articles that were selected through the literature review assessed the effectiveness
of various fonns of intervention. The most appropriate and effective one was detennjned
to be the intervention that involved one-on-one or face-to-face visits by either a physician
or plwmacist12 ) f III Doctor specific data from ptlase Jof the study together with
feedback. from thephysicians will form the basisfor the focus of the intervention which
will be used in Phase II of the study . The Department of Health want to reduc e
inappropriate antibiotic utilization immediately and are less concerned about vigorously
testing various interventions.
Slatistical Analy.ls
All data will be analyzed with SPSS , a statistical computer program. Various
frequenc ies will be calculated which will allow the determination of :
<a)overutilization rate of antibiotic prescription per total visits and per specific
diagnoses - a measureof overall antibiotic utilization, with underutilization of
antibiotics being the secondary variable;
(b) level of overall adherence to recommendations in the Ontario Anti-infective
guidelines.
The hypothesis (H,.,)oftltis study is that after the physicians have participated in the
intervention, the overutilization rate of antibiotic prescription will decrease in comparison
to the overutilization rate ofantibiotic prescription that was measured before the
intervention was implemented. The null hypothesis CHo) would be that the
overuti liza tion rate of antib iotic praaiption either remains the same or increases aft er the
inlerven tion bas been completed.
A - overutiJ ization rate of ant ibiotic:prescription after the intc:rvatt:ion
B - overuti lization rate o f antib iotic prescription before the intervention
H...= B> A
!io= BS A
A McNemar's Chi-squarrd lest wiD be used to compue the proporti on ofantibiotic
prescriptions thatarc appropriate before andafter the intervention. Theremaining
clinical assessments, the reasons for antibiotic prescription and basel ine characteristic s of
physicians and patients will be summarized through the usc ofdescriptive stati stic s.
Ethics
Since the subjects oflhi! study arc funily physicians they will be asked to sign a
consen t form (Appendix F) verifying that they ( I) asr- to parti cipate in this stud y,
(2) approve of 1llcacquisition o f information &om their patients' dwts and (3) consenl to
a physici an interview , whereby all information will be used in data analysis.. This
co nsent form expiaiDs EO the physician the mc:aswu thai wi ll be taken 10 CIISW"e thei r
con fiden tiality, their patients whosecharts will be reviewed and any relevan t infonnation
tha t will be used in the anal ysis. ArJy information capable of identi fying the patienl will
no l be revealed at any time 10 anyone other than the rescar<:hen who have collected the
information. Although the ralC!1 ofdiagnosis and prescription will be assessed, the
identity o f participating physicians will be unknown 10 the researchers .




